

Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic imaging

Cite this: *Chem. Soc. Rev.*, 2014, 43, 6570

Kai Li^a and Bin Liu^{*ab}

Polymer encapsulated organic nanoparticles have recently attracted increasing attention in the biomedical field because of their unique optical properties, easy fabrication and outstanding performance as imaging and therapeutic agents. Of particular importance is the polymer encapsulated nanoparticles containing conjugated polymers (CP) or fluorogens with aggregation induced emission (AIE) characteristics as the core, which have shown significant advantages in terms of tunable brightness, superb photo- and physical stability, good biocompatibility, potential biodegradability and facile surface functionalization. In this review, we summarize the latest advances in the development of polymer encapsulated CP and AIE fluorogen nanoparticles, including preparation methods, material design and matrix selection, nanoparticle fabrication and surface functionalization for fluorescence and photoacoustic imaging. We also discuss their specific applications in cell labeling, targeted *in vitro* and *in vivo* imaging, blood vessel imaging, cell tracing, inflammation monitoring and molecular imaging. We specially focus on strategies to fine-tune the nanoparticle property (e.g. size and fluorescence quantum yield) through precise engineering of the organic cores and careful selection of polymer matrices. The review also highlights the merits and limitations of these nanoparticles as well as strategies used to overcome the limitations. The challenges and perspectives for the future development of polymer encapsulated organic nanoparticles are also discussed.

Received 14th January 2014

DOI: 10.1039/c4cs00014e


www.rsc.org/csr

1. Introduction

Fluorescence imaging techniques have attracted great attention due to their distinguished advantages in terms of the availability of biocompatible imaging agents, maneuverable instruments, and high temporal resolution with good sensitivity.^{1–3}

^a Institute of Materials Research and Engineering, A*STAR, 3 Research Link, Singapore 117602. E-mail: cheliub@nus.edu.sg

^b Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore 117585



Kai Li

work focuses on the design and optimization of conjugated polymer/oligomer-based fluorescent nanoparticles for bioimaging applications.

Kai Li received his BE degree in Polymer Materials and Engineering from the Beijing University of Chemical Technology and ME degree in Polymer Engineering from Chungnam National University. He moved to the National University of Singapore (NUS) in 2007 to pursue his PhD degree under the supervision of Prof. Bin Liu. He is currently a research scientist in the Institute of Materials Research and Engineering (IMRE), A*Star. His



Bin Liu

design and synthesis of functional water-dispersible conjugated polymers and organic nanoparticles with exploration of their applications in sensing, imaging, therapy and optoelectronic devices. She is serving as Associate Editor of Polymer Chemistry.

Bin Liu received her BSc and MSc in Organic Chemistry from Nanjing University and PhD degree in Chemistry from the National University of Singapore (NUS) in 2001. After postdoctoral training and working as an assistant researcher at the University of California, Santa Barbara, she joined NUS in 2005. She is currently Dean's Chair Professor in the Department of Chemical and Biomolecular Engineering. Her current research focuses on the



To achieve desired signal output and high signal-to-noise ratio, a variety of fluorescent probes based on both discrete molecules and colloidal nanoparticles have been explored. While discrete small molecules (e.g. fluorescent proteins and organic dyes) have good biocompatibility and small sizes that are ideal for intracellular target labeling,^{4,5} fluorescent nanoparticles have advantages of good photostability and easy surface functionalization, which have attracted increasing attention in biomedical research.⁶ To date, a variety of fluorescent probes based on inorganic and organic nanomaterials and organic-inorganic hybrid systems have been developed for *in vitro/in vivo* sensing and imaging.^{7–13} Each class of these fluorescent nanomaterials have shown their distinct advantages. For instance, inorganic quantum dots have excellent photostability with narrow emission, which are ideal candidates for multiplex imaging.⁸ Metallic nanoclusters have subnanometer dimensions and low cytotoxicity,^{9,14} while up-conversion nanoparticles produce visible emission upon excitation with near-infrared (NIR) laser that benefits deep tissue imaging.¹⁰ For organic nanomaterials, carbonaceous dots are toxic-free and are promising alternatives to traditional inorganic quantum dots.¹¹ Combinations of organic and inorganic components, such as dye-doped or dye-decorated silica nanoparticles, often show improved photostability and higher brightness as compared to discrete dye molecules.^{12,15} As fluorescent nanomaterials containing inorganic elements face the challenge of non-biodegradability in living bodies, organic nanoparticles with organic emitters as the fluorescent core and biocompatible/biodegradable polymers as the encapsulation matrix have emerged as a new generation of promising probes for *in vivo* applications.

To date, the most popular organic emitters are small molecule dyes that are rich in variety.^{16,17} The emission of these dyes, however, is often weakened or even annihilated in aggregates, which is known as aggregation-caused quenching (ACQ).¹⁸ This phenomenon is even more serious for dyes with emission in the far-red/near-infrared (FR/NIR) tissue-transparency window. The elongated conjugation with large aromatic rings favors strong π - π interaction to quench the fluorescence.¹⁹ Using 3,3'-diethylthiadicarbocyanine iodide and Nile Red as examples, the fluorescence of dye loaded nanoparticles could be significantly reduced to almost zero at high dye loading.²⁰ In addition to the ACQ effect, dye loaded nanoparticles also share the same shortcoming of small Stokes shifts with their isolated dye molecules,^{21,22} which is unfavorable for *in vivo* imaging.

The discovery of fluorogens with aggregation-induced emission (AIE) characteristics offers a straightforward solution to the ACQ problem.²³ The AIE phenomenon is generally observed in molecules that contain rotor structures (e.g., phenyl groups) to promote fast discrete diffusion. The rotor-containing fluorogens exhibit low frequency vibrational modes in dilute solutions, which induce very fast non-radiative decay of the excited singlet states to emit faint fluorescence. In the aggregation state, these modes are eliminated by intermolecular steric interactions, which activate the radiative pathway. The fascinating features (e.g. low fluorescence as molecular species, high brightness in aggregates and large Stokes shifts) of AIE fluorogens led to booming development of polymer encapsulated AIE nanoparticles in the past two years, making them a new promising tool for imaging.

Conjugated polymers (CPs) represent the macromolecular emitters. Due to their highly delocalized π -conjugated backbones,²⁴ CPs show distinguished advantages over small organic dyes in terms of higher absorptivity, better photostability, larger Stokes shift, and stronger interaction with the encapsulation matrices. In addition, the optical properties of CPs can be feasibly customized through backbone and side-chain modifications.²⁵ To apply CPs in bioimaging, water dispersibility is the prerequisite condition, which can be endowed through either chemical modification to introduce hydrophilic side chains to afford conjugated polyelectrolytes (CPEs)^{26–30} or fabrication of CP nanoparticles.^{31–33} Earlier studies have shown that self-assembled water-soluble polymers are ideal for sensing, imaging, drug delivery and photodynamic therapy.^{27,34,35} However, it is time-consuming to design and modify each polymer to endow them with water-solubility.

The fascinating properties of CPs and CPEs have motivated researchers to look for simple strategies to bring them into aqueous media for fast screening of all the existing CPs and new ones to be developed for more specific applications. Previous reviews from several groups have discussed the synthesis and characterization of CP nanoparticles through various synthetic techniques, including polymerization, emulsion and nanoprecipitation.^{36,37} As compared to specific structural modification to synthesize each CPE,^{38,39} encapsulation of CPs using biocompatible polymers emerges as one of the most convenient strategies to transform neutral CPs into aqueous media.^{31,32,40,41} The marriage between biocompatible polymer matrices and functional CPs or AIE fluorogens thus offers new insights into the development of highly fluorescent polymer encapsulated organic nanoparticles with unprecedented brightness for bioimaging.^{31,42}

Different from fluorescence imaging which requires probes with bright fluorescence, recent discovery reveals that low fluorescence CP nanoparticles with NIR absorption are ideal probes for photoacoustic (PA) imaging. It is generally considered that large absorption coefficient at long wavelength and high nonradiative quantum yields are two dominant factors to yield strong PA signals for organic materials.⁴³ This offers new opportunities for many weakly fluorescent organic fluorogens and polymers, which has further expanded the horizon of CPs in biomedical research. As PA imaging is able to provide centimeter penetration depth with micrometer resolution, it is able to directly address the limited penetration depth for fluorescence imaging (e.g. tens to hundreds of micrometers). Due to the rapid development in the design and fabrication of polymer encapsulated AIE and CP nanoparticles for advanced biological applications, we believe that it is timely and necessary to summarize the recent progress in this area.

In this review, we summarize the latest advances in the development of polymer encapsulated CP and AIE fluorogens for fluorescence and photoacoustic imaging. We limit the scope to the work published in the past three years, with a focus on strategies for fine-tuning the nanoparticle size and brightness through precise design of light emitters and careful selection of polymer matrices. Firstly, we summarize the methods used for the formation of polymer encapsulated organic nanoparticles. We then discuss the current status of polymer-encapsulated nanoparticles based on CPs and AIE fluorogens to reveal how the interplay between light emitters and




matrices is able to control the nanoparticle size and brightness for *in vitro/in vivo* fluorescence and photoacoustic imaging. While significant attention has been focused on how to produce highly fluorescent CP and AIE nanoparticles, the emergence of dark CP nanoparticles for PA imaging should stimulate further research interest and inspire more exciting research on organic nanoparticles. Finally, perspectives for the future development of organic nanoparticles for imaging and therapy are discussed.

2. Synthesis of polymer-encapsulated organic nanoparticles

In the following discussion, “organic emitter” is used to represent all the organic fluorescent materials, including traditional dyes, CPs and AIE fluorogens. Several methods to prepare polymer-encapsulated organic nanoparticles have been developed, which include self-assembly, polymerization, macro-/micro-/mini-emulsion and nanoprecipitation. The nanoparticle sizes are sensitive to several parameters used during nanoparticle preparation, such as amphiphilicity and molecular weight of encapsulation matrices, initial concentration of emitters and the miscibility of the emitter-containing organic solvents in aqueous media. For example, Christensen and co-workers have reported that increasing the starting concentration of poly(flourene-*alt*-benzothiadiazole) (PFBT) to > 500 ppm can obviously induce the size increase of CP nanoparticles prepared by nanoprecipitation.⁴⁴ On the other hand, Feng and co-workers reported that the poly(lactic acid)-*d*- α -tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) encapsulated nanoparticles showed an average size of ~200 nm when water-miscible tetrahydrofuran (THF) was used as the organic solvent, *i.e.* they were smaller than those prepared using water-immiscible dichloromethane (DCM) as the solvent (~300 nm).^{45,46}

2.1. Self-assembly

Due to the unique chemical structures, amphiphilic polymers tend to self-assemble into nano-aggregates in aqueous solution.^{47,48} When the mixture of amphiphilic polymers and organic emitters dissolved in a “good” solvent is quickly added to an excess amount of a “poor” solvent, the hydrophobic segments tend to aggregate and encapsulate organic emitters in the core while the hydrophilic chains act as a shell to stabilize the obtained nanoparticles. On the other hand, upon conjugating organic emitters to the hydrophobic termini or side chains of amphiphilic polymers, the obtained polymer-emitter conjugates will form fluorescent nanoparticles with organic emitters embedded in the polymer matrix (Scheme 1).




Scheme 1 Schematic illustration of polymer-encapsulated organic nanoparticle preparation from self-assembly.

In addition, the hydrophilic segments could be decorated with functional groups for further conjugation with specific targeting moieties to cater to versatile biological tasks.

2.2. Polymerization


In a typical polymerization method, the organic solvent containing monomers and organic emitters is uniformly dispersed into stable and small oil droplets in the presence of an emulsifier in aqueous solution through ultrasonification. The polymerization of monomers in oil droplets starts with the addition of initiators into the emulsion to yield organic nanoparticle dispersions (Scheme 2).^{49,50} Further solvent evaporation affords the well-dispersed polymeric nanoparticles. In this method, the emitters can be either reactive or non-reactive to the monomers during polymerization.^{51,52}



Scheme 2 Schematic illustration of polymer-encapsulated organic nanoparticle preparation from *in situ* polymerization. (i) Addition of monomers and emitters in water containing an emulsifier; (ii) dispersion of monomers and emitters with sonication; (iii) addition of an initiator to initiate the monomer polymerization to yield emitter-loaded polymer nanoparticles.

2.3. Emulsion

Emulsions can be generally classified into three types based on the sizes of the droplets, which are macroemulsion, miniemulsion and microemulsion.⁵³ Miniemulsion and microemulsion are always employed to produce nanoparticles with sizes less than 500 nm, while the size of droplets in macroemulsion is larger than 1 μm .⁵² In a typical emulsion process, the emitters are dissolved in an organic solvent together with the polymer matrix to obtain a homogeneous solution. The organic solvent used in emulsion is immiscible with water (*e.g.*, dichloromethane). When the solvent is added into emulsifier-containing aqueous solution under ultrasonification or vigorous stirring, small organic droplets are stabilized by the emulsifier to generate a homogeneous “oil-in-water” emulsion. After organic solvent evaporation, stable suspension of polymer encapsulated nanoparticles in water is obtained and the surface of these nanoparticles can be used for further functionalization (Scheme 3).




Scheme 3 Schematic illustration of the preparation of polymer-encapsulated organic nanoparticles from emulsion.



2.4. Nanoprecipitation

Nanoprecipitation differs from emulsion in the organic solvents used for nanoparticle formation. Nanoprecipitation requires the solvent to be miscible with water and there is no emulsifier present in the aqueous phase.⁵⁴ In a typical nanoprecipitation process, the solution of emitters and the encapsulation matrix in an organic solvent (*e.g.*, THF) is rapidly added to an excess of water under ultrasonication. The sudden decrease of solvent hydrophobicity leads to aggregation of emitters and hydrophobic segments of the encapsulation matrix to yield nanoparticles. The hydrophilic chains of the polymeric matrix orient into the aqueous phase to facilitate further functionalization (Scheme 4).



Scheme 4 Schematic illustration of the preparation of polymer-encapsulated organic nanoparticles from nanoprecipitation.

3. Fluorescence imaging

3.1. Polymer encapsulated conjugated polymer nanoparticles

For fluorescence imaging, brightness is highly desirable for good sensitivity at a low dosage of the contrast agent with reduced side effects. One main obstacle to obtain highly emissive CP nanoparticles is that neutral CPs often have reduced fluorescence when aggregated.^{55,56} Different strategies have been developed to overcome the intrinsic quenching effect of CPs in aggregates, such as through CP design, matrix selection and nanoparticle preparation. So far, CP nanoparticles with tunable size, brightness and surface properties have been customized to meet versatile requirements in *in vitro* and *in vivo* studies.

3.1.1. Conjugated polymer design. To date, a number of CPs with different backbone structures, including poly(fluorene) (PF), poly(*para*-phenylene) (PPP), poly(*p*-phenyleneethynylene) (PPE), poly(*p*-phenylenevinylene) (PPV), poly(thiophene) (PT) and their derivatives, have been synthesized through different

polymerization methods (*e.g.*, Suzuki coupling, Heck coupling, Sonogashira coupling and oxidative polymerization). The chemical structures of several typical CPs are shown in Fig. 1. In the past, several strategies, such as using bulky monomers,⁵⁷ introducing bulky groups (*e.g.* dendrion, or polyhedral oligomeric silsesquioxane, POSS)^{58–60} to the polymer side chain or as end-cappers, designing polymers with intramolecular donor–acceptor architectures,⁶¹ and using polymer–small molecule blends,⁶² have been proved effective in mitigating polymer aggregation, leading to bright fluorescence in films.

It has been generally observed that CPs with short wavelength emission show higher fluorescence quantum yields than those with longer emission in both solution and solid state. This potentially poses new challenges as the increasing interest in *in vivo* fluorescence imaging studies requires advanced probes with FR/NIR emission, due to minimized photodamage to biological substrates, low background auto-fluorescence and deep tissue penetration in this wavelength range.⁶³ Despite the large amount of CPs developed, bright FR/NIR fluorescent CPs remain very rare.⁶⁴ Introducing donor–acceptor structures into CP backbones⁶⁵ is the most widely used strategy to realize FR/NIR emission. These CPs suffer from significantly reduced fluorescence quantum yields in aqueous media, due to severe aggregation and charge transfer induced fluorescence quenching.⁶⁶ Several strategies have been reported to optimize the FR/NIR CPs. For instance, a small amount of narrow-band-gap moieties as energy acceptors can be introduced into the CP backbones to facilitate intra- and interchain energy transfer in the aggregated state, which ensures both high absorptivity from the donor part and bright fluorescence from the acceptor units. Additionally, bulky pendants, such as POSS, can be incorporated into the FR/NIR CP backbone or side chain to effectively prevent close packing of the CPs to block energy transfer to low energy defects.⁶⁰ Considering the fact that CPs are excellent light absorbers, they are ideal energy donors that could be used to blend with NIR emitters (*e.g.* organic dyes, QDs or acceptor CPs)^{67,68} for amplified NIR fluorescence in nanoparticles.

3.1.2. Nanoparticle formulation. In 2008, McNeill and co-workers reported the synthesis of bare CP nanoparticles through nanoprecipitation for non-specific cellular imaging.⁶⁹ The lack of functional groups on bare CP nanoparticles is a great limitation for specific modification to realize targeted imaging. Additionally, the colloidal and fluorescence stabilities of bare CP nanoparticles remain susceptible to the external environment. Polymer-encapsulated CP nanoparticles thus offer new opportunities to overcome these limitations. To date,




Fig. 1 Chemical structures of PF, PPP, PPE, PPV and PT.



several biocompatible polymers with versatile functional groups have been applied for CP nanoparticle preparation, which include poly(DL-lactide-co-glycolide) (PLGA),⁷⁰ 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-(polyethylene glycol) (DSPE-PEG), polystyrene-block copolymer (PS-PEG/PSMA) and their derivatives with terminal functionality.⁷¹ It is found that polymeric matrices with higher amphiphilicity and lower molecular weight can yield CP nanoparticles with smaller sizes, *e.g.* the sizes of the nanoparticles generally follow the order PLGA > DSPE-PEG > PS-PEG/PSMA. Moreover, amphiphilic polymers with more hydrophobic segments are beneficial to increase the quantum yields of CP nanoparticles. This is because the highly hydrophobic segments in matrices intend to form more compact cores that effectively minimize the contact between CPs and oxygen or water for fluorescence quenching. For instance, the reported sizes and quantum yields of PFBT nanoparticles are highly dependent on encapsulation matrices. When PLGA was employed as the matrix, the size and quantum yield of PFBT nanoparticles were ~243 nm and 5%, respectively.⁷⁰ The sizes were decreased to ~55 nm and ~7 nm using DSPE-PEG and PS-PEG as the polymeric matrices, and the corresponding quantum yields were improved to 18% and 75%, respectively.^{44,72} The absorption

and emission maxima, the sizes, colloidal stability and quantum yields of the reported polymer encapsulated CP nanoparticles together with their matrices and applications are summarized in Table 1.

3.1.2.1. Poly(DL-lactide-co-glycolide) nanoparticles. As a Food and Drug Administration approved polymer, biocompatible poly(DL-lactide-co-glycolide) (PLGA copolymer) has been actively used as a carrier for drug delivery.^{73–75} PLGA-encapsulated CP nanoparticles with sizes of 240–270 nm and ~190 nm could be synthesized through microemulsion and nanoprecipitation methods, respectively. The terminal carboxyl groups of PLGA allow further conjugation of functional moieties before or after nanoparticle formulation. Liu and co-workers developed a general strategy through a single emulsion method to fabricate a series of CP-loaded PLGA nanoparticles with emission covering the range from 400 to 700 nm.⁷⁰ Although the CP nanoparticles were effective in targeted cellular imaging, the quantum yields of the as-prepared CP nanoparticles were 4–25 fold lower than those of CPs in tetrahydrofuran (THF) solutions, due to extensive CP aggregation in nanoparticles which promotes non-radiative decay.⁷⁶ To reduce the close-packing of CP molecules upon nanoparticle formation,

Table 1 Summary of polymer encapsulated CP nanoparticles for fluorescence imaging applications

CPs	Matrix	Size ^a (nm)	λ_{ex} (nm)	λ_{em} (nm)	QY (%)	Colloidal stability	Targeting ligands	Application
CP1	PLGA/PLGA-PEG-NH ₂	~250	411	479	19	—	Trastuzumab	<i>In vitro</i> targeted cell imaging ⁷⁷
CP2	DSPE-PEG-maleimide	28	528	686	14	—	Affibody	<i>In vitro</i> targeted cell imaging ⁶⁰
CP3	PLGA-COOH	235	434	481	11	—	Affibody	<i>In vitro</i> targeted cell imaging in a mixture (single laser excitation) ⁸¹
CP4		193	436	622	19	—	RGD	
CP5	PLGA/PLGA-PEG-folate	180	516	636	7	—	Folate	<i>In vivo</i> dual-modality tumor imaging (fluorescence, MRI) ⁸⁶
CP6	DSPE-PEG-biotin	55	460	545	18	—	Biotin	<i>In vitro</i> targeted cell imaging ⁴⁴
CP7	DSPE-PEG DSPE-PEG-folate	80	550	698	27	^c	Folate	<i>In vitro/in vivo</i> targeted cell/tumor imaging ⁹⁴
CP8	DSPE-PEG	36	461	582	32	^d	Tat peptide	<i>In vitro</i> long-term cell tracing ⁹⁵
CP9/IR775	DSPE-PEG					—	No	<i>In vivo</i> RON imaging ⁹⁶
CP6	PSMA	15	—	—	28	^e	No	<i>In vitro</i> bioorthogonal labeling of cellular targets ⁹⁷
CP10		10	—	580	60	—	Streptavidin	
CP11	PS-PEG-COOH	16	—	540	18	—	Streptavidin	<i>In vitro</i> photoswitching imaging ¹¹¹
CP6/CP12		—	—	650	55	—	Chlorotoxin	
CP4/NIR775/Luc8		40	—	778	—	—	RGD	<i>In vivo</i> brain tumor targeting; ¹¹² <i>in vitro</i> tracking of IGF1R ¹¹³
								Bioluminescence resonance energy transfer for <i>in vivo</i> tumor targeted imaging ¹¹⁶
CP6	PS-PEG-COOH/PIMA	7	460	540	75	^f	Streptavidin	Protein location and orientation ⁷²
CP6 (C6 side chain)	F127/silica	12 ^b	460	545	70–75	^g	No	<i>In vivo</i> brain vascular imaging ¹¹⁹

^a The sizes of nanoparticles were determined by dynamic light scattering (DLS) unless otherwise specified. ^b The sizes of nanoparticles were determined by TEM. ^c The size remains the same upon incubation in PBS buffer at 37 °C for 7 days. ^d No precipitation observed upon storing at 4 °C for 3 months. ^e The size increased from ~15 nm to >2000 nm in the presence of 1 mM Cu²⁺ in water. ^f The size remains stable for months at 4 °C. ^g No obvious size variation observed in 10 days.



attaching POSS as an end-capper to poly(fluorenevinylene) led to **CP1**, and the **CP1**-loaded PLGA nanoparticles showed an improved quantum yield of 19% relative to 11% for poly(fluorenevinylene).⁷⁷ The surface carboxyl groups of PLGA nanoparticles allowed further conjugation with trastuzumab through 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated coupling reaction. The trastuzumab-functionalized **CP1**-loaded nanoparticles were then successfully used for specific discrimination of SK-BR-3 cells from MCF-7 and NIH/3T3 cells. In addition to end chain modification, POSS has also been incorporated into the side chains of a polyfluorene derivative containing the narrow-band-gap moiety, 4,7-di(thiophen-2-yl)-2,1,3-benzothiadiazole (DBT), to yield **CP2** with bright FR/NIR emission in aggregates.⁶⁰ **CP2**-based nanoparticles have a fluorescence quantum yield of 13.6% in water, which is ~ 7 -fold higher than that of the nanoparticles prepared using the counterpart without POSS attachment. Further surface immobilization with thiol-containing anti-HER2 affibody facilitated *in vitro* targeted imaging of HER2-overexpressed SK-BR-3 breast cancer cells. It is noteworthy that the higher quantum yield of **CP2** nanoparticles ensures dramatically improved fluorescence contrast during confocal imaging (Fig. 2).

By introducing a small portion of energy acceptors into CP backbones, efficient energy transfer from the donor to the acceptor could be triggered in the aggregate state,^{78–80} leading to amplified acceptor emission at the expense of the donor fluorescence. As such, CPs with energy donor–acceptor design are ideal to yield fluorescent nanoparticles with different emission colors upon single wavelength excitation at the same donor absorption maximum. **CP3** is an analogue of **CP1**

with green fluorescence. Introducing a small portion of 2,1,3-benzothiadiazole (BT) units into the **CP3** backbone led to **CP4** with significantly red-shifted emission in aggregates because of aggregation enhanced energy transfer from the fluorenevinylene segments to the electron-deficient BT units.⁸¹ PLGA-encapsulated green and red nanoparticles with an average size of ~ 190 nm and surface carboxyl groups were then synthesized through a single emulsion method. The obtained **CP3** and **CP4** nanoparticles have similar absorption maxima (434 nm and 436 nm) while their emission spectra are well-separated with maxima at 483 nm and 622 nm, respectively (Fig. 3a). The **CP3** and **CP4** nanoparticles were subsequently modified with anti-HER2 affibody and RGD peptide, which are specific targeting ligands to HER2 and integrin receptor, respectively. Owing to the specificity of targeting biomolecules and the distinct emission spectra, the well-separated fluorescence signals from affibody-**CP3** and RGD-**CP4** nanoparticles at the surface of SK-BR-3 cells and HT-29 cells allow simultaneous differentiation of the two cancer cell lines in a living cell mixture (Fig. 3b). As compared to single target detection, simultaneous identification of multiplex targets under single laser excitation has several advantages such as minimum instrument requirement, short testing time, reduced sample consumption and low overall cost.⁸²

As compared to CP nanoparticles with single modality, dual-modality nanoparticles offer great potential to satisfy the increasing requirements in advanced bioimaging applications through detection in both modes.⁸³ In this regard, Green and co-workers reported the fabrication of fluorescent-magnetic nanoparticles through co-encapsulation of CPs and iron oxides (IOs) for cell imaging.⁸⁴ The magnetic property was well preserved and the nanoparticles could be internalized by living SH-SY5Y cells for fluorescence imaging. However, the fluorescence of CPs was significantly sacrificed due to the quenching of CP fluorescence by IOs.⁸⁵ To solve this problem, Liu and co-workers developed a facile strategy to synthesize similar nanoparticles with minimized fluorescence quenching by co-encapsulation of **CP5** and lipid-coated IOs into a mixture of PLGA and PLGA-PEG-folate through a solvent extraction emulsion method (Fig. 4a).⁸⁶ The yielded nanoparticles show super-paramagnetic properties with a saturated magnetization value of 3.42 emu g^{-1} without sacrificing the fluorescence, due to the lipid coating on iron oxides that acts as an effective barrier to minimize interaction between **CP5** and IOs. The resulted dual-modality nanoparticles have an average size of ~ 180 nm and are able to be readily internalized by MCF-7 cells without obvious cytotoxicity. The emission maximum locates at 636 nm with a large Stokes shift of 120 nm, which favors *in vivo* fluorescence imaging with high contrast (Fig. 4b).⁸⁷ Additionally, a T_2 -weighted magnetic resonance (MR) signal is observed at the tumor site, which is in good accordance with the fluorescence imaging study (Fig. 4c). The prominent tumor uptake of nanoparticles could be attributed to the combined passive targeting and folate receptor-mediated active targeting effect. Later, the same group




Fig. 2 Chemical structures of **CP1** and **CP2**. Confocal images of fixed SK-BR-3 breast cancer cells incubated with (a) affibody-functionalized **CP2** nanoparticles and (b) affibody-functionalized nanoparticles prepared from the counterpart of **CP2** without POSS. The images were taken under the same experimental conditions (reprinted with permission from ref. 60, Copyright 2013 Royal Society of Chemistry).






Fig. 3 Chemical structures of CP3 and CP4. (a) UV-Vis and PL spectra of CP3 (black) and CP4 (red) nanoparticles. (b) Confocal images of a mixture of suspended living SK-BR-3 cells (green) and HT-29 cells (red) stained with affibody-CP3 and RGD-CP4 nanoparticles at 4 °C ($\lambda_{\text{ex}} = 405 \text{ nm}$) (reprinted with permission from ref. 81, Copyright 2011 American Chemical Society).




Fig. 4 Chemical structure of CP5. (a) Schematic illustration of CP5-based dual-modality nanoparticles with surface folate groups. (b) Representative *in vivo* fluorescence images of the mouse injected with CP5 nanoparticles acquired at 1 h, 6 h and 18 h post-injection. (c) MR images of the mouse treated with CP5 nanoparticles at 0 and 5 h post-injection. Red circles in (c) indicate the tumor region (reprinted with permission from ref. 86, Copyright 2012 Wiley-VCH).

reported the application of $\sim 5 \text{ nm}$ Au dots and CP5 co-loaded nanoparticles for fluorescence and dark field dual-modal *in vitro* targeted cancer cell imaging.⁸⁸ TEM results showed that Au dots were eccentrically located at one side of the nanoparticles due to evaporation-induced phase separation between Au dots and the polymer matrix,⁸⁹ which minimized the fluorescence quenching of CPs by Au dots. As a result, CPs have great potential in the construction of multi-modality nanoprobes for versatile *in vitro* and *in vivo* applications.

Based on the several examples discussed above, it is obvious that the CP nanoparticles with the PLGA matrix often have sizes around 200 nm with medium to low fluorescence quantum yields. The high loading capacity of PLGA nanoparticles is ideal for co-encapsulation of several imaging or therapeutic agents with CPs to yield multimodality probes for imaging and therapy.^{86,90} However, PLGA based nanoparticles suffer from obvious shortcomings, *e.g.* the long-term colloidal stability is not ideal due to their large size and fast biodegradability. The excess of carboxyl groups on the nanoparticle surface also makes them vulnerable to aggregation in the presence of divalent metal ions.

3.1.2.2. DSPE-PEG nanoparticles. As amphiphilic macromolecules with favorable biocompatibility, DSPE-PEG derivatives are ideal matrices to encapsulate hydrophobic components to yield nanoparticles with small size ($< 100 \text{ nm}$) and excellent colloidal stability due to the presence of surface PEG. In addition, the utilization of different DSPE-PEG derivatives can afford nanoparticles with surface targeting ligands or functional groups with tunable densities for post-functionalization.^{91,92} Christensen and co-workers prepared a series of DSPE-PEG-encapsulated CP nanoparticles with average sizes of 55–83 nm in water, determined by DLS.⁴⁴ Using CP6 as an example, DSPE-PEG encapsulated fluorescent nanoparticles with tunable surface groups






Fig. 5 Chemical structure of **CP6**. Confocal (a) bright field and (b) fluorescence images of J774A cells labeled with biotinylated DSPE-PEG-encapsulated **CP6** nanoparticles (reprinted with permission from ref. 44, Copyright 2011 Royal Society of Chemistry).

(e.g., carboxyl group, biotin) showed similar sizes (~ 55 – 58 nm) and quantum yields (~ 17 – 19%). In addition, biotin-**CP6** nanoparticles were able to specifically image surface receptor CD16/32 of J774A cells using biotinylated anti-CD 16/32 monoclonal antibody as a primary binding element and streptavidin as a linker in a sandwich format (Fig. 5).

To further develop bright CP nanoparticles with FR/NIR emission, a series of CPs were designed to contain narrow-band-gap energy acceptors in CP backbones. The design takes advantages of intra- and interchain energy transfer in nanoparticles with minimized fluorescence quenching due to acceptor dilution.⁹³ A successful example is **CP7**, which contains two narrow bandgap moieties at a ratio of 80 (donor) to 20 (acceptor) in the backbone.⁹⁴ When the donor segment was excited at 457 or 488 nm, efficient energy transfer occurred to facilitate FR/NIR emission. Using the mixture of DSPE-PEG and DSPE-PEG-folate as the matrix, the obtained folate-**CP7** nanoparticles have an average size of ~ 77 nm in water while the excitation and emission peaks are located at 465 nm and 698 nm, respectively. The fluorescence quantum yield of **CP7** nanoparticles is $\sim 27\%$ in water, which is among the highest for single component CP nanoparticles with FR/NIR emission. *In vitro* and *in vivo* studies reveal that the folate-functionalized nanoparticles have good targeting ability for folate receptor-overexpressed cancer cells and tumor tissues with low cytotoxicity and good biocompatibility. Obvious fluorescence signals were also observed in tumor, liver and spleen tissues at 24 h post-injection. Fig. 6 shows the semiquantitative biodistribution analysis, which suggests that the ratio of average fluorescence in the tumor tissue to that in the liver is 1.7 for folate-**CP7** nanoparticle-treated mice. In addition, the fluorescence from the tumor in mice treated with folate-**CP7** is ~ 1.9 -fold brighter than that for **CP7** nanoparticle-treated ones, indicating the obvious targeting effect due to folate functionalization. Further *in vivo* experiments using tumor-free or H22 tumor-bearing ICR mice revealed that the folate-**CP7** nanoparticles have no obvious *in vivo* toxicity. These results clearly indicate that CP nanoparticles can serve as an effective FR/NIR fluorescent probe for targeted *in vivo* fluorescence imaging and cancer diagnosis.




Fig. 6 Chemical structure of **CP7** and semiquantitative biodistribution analysis of folate-**CP7** nanoparticles and **CP7** nanoparticles in H22 tumor-bearing mice at 24 h post-injection (reprinted with permission from ref. 94, Copyright 2013 Wiley-VCH).

Besides chemical modification of CPs, fine-tuning the size and morphologies of CP molecules in nanoparticles is another effective strategy to optimize their brightness and fluorescence quantum yields.⁹⁵ Using DSPE-PEG as the encapsulation matrix, the initial feed concentration of **CP8** in THF has a significant impact on the internal morphologies of CP molecules although the average sizes of the obtained nanoparticles are similar (~ 36 nm). For instance, the higher initial **CP8** concentration at 1.00 mg mL^{-1} led to nanoparticles with a typical core-shell structure and a fluorescence quantum yield of 17% (Fig. 7a). As the initial CP concentration decreased, the core-shell structure was transformed into dark dot embedded nanoparticles. At the initial **CP8** concentration of 0.25 mg mL^{-1} , single-chain CP dot (~ 2 – 3 nm) embedded nanoparticles were obtained with a fluorescence quantum yield of 32%. This is due to the reduced non-radiative recombination from inter- and/or intra-chain interactions in the single-chain morphology, as evidenced by the lifetime results. The **CP8** nanoparticles showed similar sizes (~ 30 nm by DLS) in water when fabricated using either DSPE-PEG-COOH, DSPE-PEG-NH₂ or DSPE-PEG-maleimide as the encapsulation matrix. Further conjugation with a cell penetrating *trans*-activator of transcription (Tat) peptide, Tat (RKKRRQRRRC), was achieved *via* carbodiimide-mediated coupling reaction for carboxyl- and amine-terminated nanoparticles or through click reaction between maleimide-terminated nanoparticles and thiol-labeled Tat. All three groups of Tat-functionalized nanoparticles showed better long-term cell tracing ability than the commercial Qtracker[®] 585 labeling kit. The Tat-**CP8** nanoparticles prepared using the DSPE-PEG-maleimide matrix have the highest cell internalization efficiency (99.97%) and the best cell tracing performance of up to nine generations as confirmed by confocal microscopy (Fig. 7b and c).






Fig. 7 Chemical structure of **CP8** and (a) TEM images of the nanoparticles prepared from different concentrations of **CP8** in the feed: 1.00, 0.50 and 0.25 mg mL⁻¹ (from left to right) using DSPE-PEG as the matrix. Confocal images of MCF-7 cancer cells labeled with 2 nM (b) Tat-**CP8** nanoparticles prepared using the DSPE-PEG-maleimide matrix or (c) Qtracker[®] 585, after subculturing for different generations (G). All images in (b) and (c) share the same scale bar of 30 μm (reprinted with permission from ref. 95, Copyright 2013 Wiley-VCH).

In addition to cellular imaging, Rao and co-workers reported the synthesis of CP based dual color nanoparticles for *in vivo* imaging of reactive oxygen and nitrogen species (RONS) in inflammatory microenvironments in living mice.⁹⁶ **CP9** was first encapsulated in DSPE-PEG and DSPE-PEG-NH₂ to yield NIR emissive nanoparticles with an emission maximum at 678 nm and a fluorescence quantum yield of 18%. The surface amine groups facilitated subsequent conjugation of carboxyl-terminated IR775 (IR775COOH) onto the nanoparticle surface (Fig. 8a). Upon excitation of **CP9**, the nanoparticles exhibited two emission peaks at 678 and 818 nm due to incomplete Förster resonance energy transfer (FRET) from **CP9** to IR775, resulting in significantly reduced quantum yield from 18% to 3%. Upon gradual addition of RONS such as ONOO⁻ to the nanoparticle solution, the emission peak at 678 nm increases with the concurrent loss of emission at 818 nm. This was due to the rapid oxidative cleavage of the oligomethine moiety of the IR775, which diminished FRET and recovered the donor fluorescence at 678 nm. Thereby, the FRET nanoparticle has a sensitive spectral change from a dual-peak profile to a single one upon RON activation. The performance of **CP9**/IR775 nanoparticles in *in vitro* RON imaging was carried out in the RAW264.7 cell line. As shown in Fig. 8b, only weak fluorescence from the cells was observed upon incubation with the nanoparticles. In contrast, cells pre-treated with bacterial cell wall lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate (PMA) that could elicit the production of RONS showed strong fluorescence, indicating the recovery of **CP9** fluorescence

activated by RONS under the same inflammatory condition. The cell fluorescence remains low in the presence of *N*-acetylcysteine (NAC), a general antioxidant that can effectively block the oxidative cleavage of IR775. The FRET nanoparticles also showed specific RON detection ability at inflammation sites in living bodies.

As discussed above, the nanoparticles made from DSPE-PEG have sizes in the range of 30–90 nm, which are smaller than those with PLGA because of the higher amphiphilicity and lower molecular weight of DSPE-PEG. As shown in Table 1, DSPE-PEG encapsulated CP nanoparticles also show good colloidal stability in aqueous media. More importantly, the versatile surface functional groups (*e.g.*, carboxyl, amine, maleimide, biotin) of DSPE-PEG derivatives provide more opportunities for further surface functionalization. The surface PEG segments are also able to prolong the circulation time of DSPE-PEG nanoparticles in blood, which is highly desired in living animal studies.⁹⁷ As a consequence, the DSPE-PEG encapsulated CP nanoparticles have been involved in a wide range of imaging applications, including *in vitro/in vivo* targeted imaging, long-term cell tracing and *in vivo* detection of reactive oxygen and nitrogen species, as summarized in Table 1.

3.1.2.3. Polystyrene block copolymer nanoparticles. Polystyrene (PS) based block copolymers were primarily used in Chiu's group to produce CP dots with very small sizes (<20 nm) for cellular imaging applications.³¹ They recently reviewed CP dots with fine-tuned surface properties for specific *in vitro* and






Fig. 8 Chemical structures of **CP9** and **IR775COOH**. (a) Schematic illustration of RON detection using **CP9/IR775** FRET nanoparticles. (b) Fluorescence images of live murine macrophages (RAW 264.7) incubated with **CP9/IR775** nanoparticles. From left to right: untreated cells, cells successively treated with LPS and PMA, and cells pre-treated with NAC before incubation with LPS and PMA, followed by NAC treatment. All the images share the same scale bar of 20 μm (reprinted with permission from ref. 96, Copyright 2013 Wiley-VCH).

in vivo targeted imaging and sensing of intracellular species (e.g., oxygen, pH and temperature).³¹ In this section, only the latest progress is summarized while specific examples are selected to highlight the impact of polymer matrix selection on nanoparticle fluorescence.

Considering the ultra-hydrophobicity of PS backbones, PS-containing amphiphilic block copolymers are promising choices to encapsulate CPs to form compact cores with very small sizes (7–15 nm). In 2011, Chiu's group reported the synthesis of **CP6** based nanoparticles in the presence of poly(styrene-*co*-maleic anhydride) (PSMA).⁹⁸ The obtained nanoparticles have an average diameter of ~ 15 nm in water with abundant surface carboxyl groups to facilitate further functionalization. Of particular significance is that the small size of as-prepared nanoparticles is highly desirable for sub-cellular imaging, which is able to avoid the problems encountered by large-sized particles, such as poor mass transfer and non-specific adsorption. The same group further explored the application of streptavidin-tagged **CP10** based nanoparticles (~ 12 nm in water) for imaging microtubules in HeLa cells.⁹⁹ The streptavidin on the nanoparticle surface allowed them to specifically bind to subcellular microtubules in the presence of biotinylated monoclonal anti- α -tubulin antibody (Fig. 9).

The same group subsequently reported that by using PS-PEG-COOH as the polymer matrix it was possible to obtain **CP6** nanoparticles with excellent colloidal stability.⁷¹ Further addition of a dodecylamine-grafted poly(isobutylene-alt-maleic anhydride) (PIMA) as the co-encapsulation matrix and the use of a low concentration of **CP6** in the feed yielded very small nanoparticles (7 nm in diameter) with up to 75% fluorescence




Fig. 9 Chemical structure of **CP10**. (a) Surface functionalization of **CP10** based nanoparticles and subsequent streptavidin bioconjugation via EDC-mediated coupling reaction. (b) Confocal images of microtubules in HeLa cells labeled with streptavidin-functionalized **CP10** nanoparticles (reprinted with permission from ref. 99, Copyright 2012 Royal Society of Chemistry).

quantum yield in water.⁷² Careful investigation of the huge improvement in quantum yield revealed that the low mass ratio of **CP6** to the encapsulation matrix (1:45) played an essential role. On average, each nanoparticle contains one **CP6** chain, which significantly minimizes the fluorescence quenching






Fig. 10 Chemical structure of **CP11** and the TEM image of **CP11** nanoparticles using PS-PEG-COOH as the encapsulation matrix (reprinted with permission from ref. 111, Copyright 2012 American Chemical Society).

through CP molecule aggregation.¹⁰⁰ Single particle imaging results suggested that the brightness of individual nanoparticles was nearly identical to that of Qdot 525 upon excitation at 488 nm. Further conjugation of the **CP6** nanoparticles with streptavidin facilitated their application in monitoring both protein location and the changes in protein orientation upon excitation with a polarized light.

On the other hand, the large extinction coefficient and highly delocalized backbone structure make CPs excellent candidates as energy donors to construct fluorescent probes based on FRET.¹⁰¹ By incorporating energy acceptors with versatile optical properties into CPs through either a non-covalent or covalent approach, nanoparticles with photoswitchable fluorescence, NIR emission and amplified acceptor signals have been developed for oxygen sensing, intracellular pH/temperature sensing, *etc.*^{102–105} Taking fluorescence photoswitching probes as an example, they have become increasingly important in super resolution imaging, *in vivo* protein concentration determination and protein trafficking in living cells.^{106–108} The photoswitchable probes have been realized through co-loading CP and a photochromic molecule (*e.g.*, diarylethene) into polymer matrices.^{109,110} In addition, covalent attachment of spiropyran to the side chain of a copolymer led to **CP11**, which upon encapsulation with PS-PEG-COOH yielded **CP11** nanoparticles with an average size of ~ 16 nm by DLS (Fig. 10).¹¹¹ The repeatable modulation of fluorescence was achieved by UV irradiation that could convert spiropyran into its visible-absorbing merocyanine form, which can efficiently quench the fluorescence of **CP11** *via* FRET. On the other hand, exposure under visible light recovered the spiropyran, which resulted in fluorescence regeneration. As compared to co-loaded CP/photochromic molecule nanoparticles,^{109,110} the molar ratio of CP to photochromic molecule is well-controlled in **CP11**, so that batch-to-batch variation in nanoparticles generated from the non-covalent blending approach can be avoided.

Energy donor-acceptor based nanoparticles have also been prepared by simultaneous encapsulation of two different CPs into the same polymer matrix to result in large absorption cross-sections in the visible range and high quantum yields in FR/NIR emission.¹¹² Howarth and co-workers reported that **CP6/CP12** hybrid nanoparticles can be prepared through encapsulation with PS-PEG-OH or PS-PEG-COOH, which led to hydroxy- and carboxy-**CP6/CP12** nanoparticles with the same emission maximum at 635 nm. The nanoparticles with the PS-PEG-OH matrix showed dramatically reduced non-specific

cell binding as compared to those based on the PS-PEG-COOH matrix.¹¹³ For example, nonspecific binding of carboxy-**CP6/CP12** nanoparticles to mammalian cells and glass coverslips was obvious in the presence of 100 nM Ca^{2+} in the extracellular medium. In contrast, only minimal nonspecific binding of hydroxy-**CP6/CP12** nanoparticles to cells and coverslips was observed (Fig. 11). Owing to the low nonspecific binding of the hydroxy-**CP6/CP12**-streptavidin nanoparticles, they have been successfully used to track the dynamics of Type I insulin-like growth factor receptor (IGF1R) on breast cancer cells.




Fig. 11 Chemical structure of **CP12**. Bright-field and fluorescence images of MCF-7 cancer cells incubated with different concentrations of (a) hydroxyl-**CP6/CP12** nanoparticles and (b) carboxy-**CP6/CP12** nanoparticles for 10 min in the presence of different concentrations of Ca^{2+} in extracellular media. All images share the same scale bar of 10 μm (reprinted with permission from ref. 113, Copyright 2013 American Chemical Society).






Fig. 12 Chemical structures of **CP13** and **NIR775**. Schematic illustration of self-luminescing BRET-FRET NIR polymeric nanoparticles (reprinted with permission from ref. 116, Copyright 2012 Nature Publishing Group).

For fluorescence imaging, the light penetration often limits the imaging depth, due to the absorption and scattering of optical photons in tissues.¹¹⁴ To address this challenge, the concept of self-luminescing hybrid probes based on the principle of bioluminescence resonance energy transfer (BRET) from a bioluminescent protein to QDs offers new research opportunities.¹¹⁵ Rao and co-workers designed self-luminescing NIR nanoparticles by integrating BRET and FRET in an energy transfer relay.¹¹⁶ The self-luminescing NIR nanoparticles were prepared by nanoprecipitation using **CP13** and **NIR775** as the emitters and PS-PEG-COOH as the matrix, followed by conjugation with a bioluminescent eight-mutation variant of *R. reniformis luciferase* (*Luc8*) and RGD peptide (Fig. 12). Three emission peaks from *Luc8*, **CP13** and **NIR775** are located at 480, 594 and 778 nm, respectively, indicating efficient BRET from *Luc8* to **CP13**, followed by FRET from **CP13** to **NIR775**. Upon intravenous administration of the nanoparticles into mice, strong NIR fluorescence signals were observed from the lymphatic networks, including neck lymph nodes, axillary lymph nodes, inguinal lymph nodes and lateral thoracic lymph nodes. Comparison between the bioluminescence imaging and fluorescence imaging ($\lambda_{\text{ex}} = 465 \text{ nm}$) was conducted by intravenous injection of the

self-luminescing nanoparticles into mice bearing exografted tumors. It was found that the signal ratio between the tumor and background from bioluminescence imaging was ~ 10 – 50 fold higher than that from fluorescence imaging at each time point post-injection. The novel self-luminescing nanoparticles provided highly improved sensitivity through bioluminescence imaging in *in vivo* studies.

As compared to PLGA and DSPE-PEG derivatives, PS-containing copolymers are likely to form more compact hydrophobic cores during self-assembly due to the high hydrophobicity of PS. The compact hydrophobic cores are beneficial to reduce the contact of encapsulated CP molecules with water, leading to high fluorescence quantum yields. In addition, PS-containing block copolymers can afford very small size nanoparticles in water due to the low molecular weight and ultra-hydrophobic PS segments. The small sizes ($\sim 15 \text{ nm}$) of PSMA/PS-PEG nanoparticles make them promising in intracellular microtubule labelling, *in vitro* membrane receptor tracking and *in vivo* brain tumor imaging. However, the PSMA-encapsulated nanoparticles suffer from poor colloidal stability in aqueous media that have either high ionic strength or bivalent metal ions, which can be improved using polyelectrolyte coating.¹¹⁷ It is important to note that the **CP6** based






Fig. 13 Single-particle fluorescence images of (a) **CP6** nanoparticles, (b) IgG-Alexa 488, and (c) Qdot 565 obtained under identical conditions. (d) Signal and background ratios for a single **CP6** nanoparticle, single IgG-Alexa 488 and single Qdot 565. (e) Intensity distributions of single-particle fluorescence for the three probes under an excitation power of 4 mW. (f) Single-particle photobleaching trajectories. Images in (a), (b) and (c) share the same scale bar of 5 μm (reprinted with permission from ref. 71, Copyright 2010 American Chemical Society).

PS-PEG-COOH nanoparticles show much higher brightness as compared to IgG-Alexa 488 and Qdot 565 in single particle imaging (Fig. 13a–c). Statistical analysis reveals that the **CP6** nanoparticles exhibit an order-of magnitude improvement in the signal-to-background ratio (Fig. 13d and e). More importantly, the pronounced fluorescence intermittency of QDs, referred to as blinking, is absent in **CP6** nanoparticles, but is obvious for Qdot 565 (Fig. 13f). Flow cytometry data suggest that the average brightness of **CP6** nanoparticle-labeled cells is ~25-fold and ~18-fold higher than that of the cells labeled with Qdot 565-IgG and Alexa-IgG, respectively. In addition, the **CP6** nanoparticles also show good colloidal stability, which can be kept for over 6 months. Indeed, **CP6** is the most widely used CP for nanoparticle fabrication, which has been used for targeted cellular imaging,⁴⁴ protein location detection⁷² and *in vivo* vascular imaging.¹¹⁸

3.1.2.4. F127 nanoparticles. F127 is a biocompatible triblock copolymer composed of a central hydrophobic chain of poly(propylene oxide) (PPO) connected with two hydrophilic

chains of PEG. Due to the long hydrophobic PPO segments and amphiphilic property, F127 can efficiently encapsulate hydrophobic agents with a compact core to efficiently prevent contact of CP molecules with oxygen and water to reduce the quenching effect.¹¹⁹ Liu and co-workers reported the synthesis of PFBT-loaded F127 micelles with a size of ~10 nm in water. The PFBT used in this study is an analogue of **CP6** with six carbons in the side chains. At a matrix to PFBT weight ratio of 200:1, the quantum yield of the obtained F127 nanoparticles was 70%, which is much higher than that for PFBT-loaded DSPE-PEG nanoparticles (40%) prepared under the same conditions. As compared to DSPE-PEG, the more hydrophobic PPO segments can entangle with PFBT backbones more efficiently to isolate CP molecules in the matrix, leading to reduced interchain interaction with fluorescence quantum yield enhancement.¹²⁰ Further coating the F127 micelles with a silica layer resulted in nanoparticles with excellent photostability and an improved quantum yield of 75%. Single particle imaging studies (Fig. 14) suggest that on average, each silica-coated F127-PFBT nanoparticle (~12 nm) emits a similar total




Fig. 14 Histograms of the total number of photons collected for (a) silica-coated F127-PFBT nanoparticles and (b) DSPE-PEG-PFBT nanoparticles. $\lambda_{\text{ex}} = 488$ nm. Insets show the TEM images of (a) and (b), respectively.

number of photons as the DSPE-PEG-PFBT nanoparticle (~ 30 nm). The silica-coated F127-PFBT nanoparticles also showed a large two-photon absorption action cross-section value of 814 GM at 810 nm based on CP chain concentrations. After intravenous injection of the nanoparticles, the major blood vessels and microvasculature deep in the brain that lies beyond the pia matter ($500 \mu\text{m}$) could be clearly visualized upon 800 nm excitation. In addition, no large aggregates were observed in the brain blood vessels, due to the surface protection of PEG segments. Although the fluorescence quantum yield of F127 encapsulated nanoparticles is very high, the brightness in each nanoparticle is limited by the total number of emitters encapsulated.

3.2. AIE fluorogen based nanoparticles

As aggregation of organic emitters is a natural process during nanoparticle synthesis, fluorogens with AIE characteristics are ideal to construct highly fluorescent nanoparticles. The development of various AIE fluorogens, the restriction of intramolecular rotation (RIR) mechanism together with their potential applications have been discussed in detail in previous

publications.^{121–123} This part only covers the recent progress in AIE nanoparticles, with a special focus on creating long wavelength emissive AIE nanoparticles for bioimaging applications. The general strategies to yield fluorogens with long wavelength emission are to increase their conjugation length or through introduction of donor–acceptor structures.¹²⁴ These fluorogens often show low fluorescence in the solid state, due to strong π – π interactions.¹²⁵ Tang *et al.* discovered that conjugation between a typical AIE unit (*e.g.* tetraphenylethylene (TPE)) and conventional ACQ molecules (AIE + ACQ) could effectively transform them into AIE fluorogens with red-shifted emission. For example, as shown in Fig. 15a, **A1** was obtained through attachment of two TPE pendants to perylene-3,4:9,10-tetracarboxylic bisimide with ACQ characteristics.¹²⁶ **A1** shows the typical AIE signature: the fluorescence of **A1** in THF solution is very faint, but it steadily increases upon addition of water into THF due to the formation of aggregates. This simple molecular transformation strategy has also been successfully employed in the synthesis of FR/NIR AIE fluorogens through conjugation of TPE with other AIE units (AIE + AIE) or fluorogens with twisted intramolecular charge transfer (TITC) characteristics (AIE + TITC).




Fig. 15 (a) A typical AIE phenomenon: plot of $I/I_0 - 1$ as a function of water fraction in THF–water mixtures, where I and I_0 are the fluorescence intensities of **A1** in THF–water mixtures in the presence and absence of water, respectively (reprinted with permission from ref. 126, Copyright 2012 Royal Society of Chemistry). (b) Plot of the fluorescence intensity versus the weight ratio of **A2** in BSA nanoparticles (reprinted with permission from ref. 127, Copyright 2012 Wiley-VCH).



Table 2 Summary of polymer encapsulated AIE nanoparticles for fluorescence imaging applications

AIE fluorogen	Matrix	Size ^a (nm)	λ_{ex} (nm)	λ_{em} (nm)	QY (%)	Colloidal stability	Targeting ligands	Application
A1	DSPE-PEG-folate	57	514	680	8	—	Folate	<i>In vitro</i> targeted cell tracing ¹²⁶
A2	BSA	148	505	668	12	—	No	<i>In vivo</i> cell imaging ¹²⁷
A3	Chitosan	—	—	—	—	—	No	<i>In vitro</i> cell tracing ¹²⁸
A4		200–400 ^b	—	—	25	—	No	<i>In vitro</i> cell imaging ¹²⁹
A5	DSPE-PEG derivatives	<30 ^b	435	577	—	—	RGD peptide	<i>In vivo</i> SLN mapping and targeted tumor imaging ²⁰
A6	In situ polymerization	30	511	671	24	^e	Tat peptide	<i>In vitro/in vivo</i> cell tracing ^{132,134} <i>In vivo</i> vascular imaging ¹³³
A7		33	423	539	58	^f	Tat peptide	<i>In vitro</i> cell tracing and nucleus imaging ¹³⁶
A8		36	480	619	55	^g	NLS Tat peptide	
A9		38	480	617	67	—	NLS Tat peptide	<i>In vivo</i> imaging ¹⁴⁰
A6/NIR 775		30 ^b	—	—	9	—	No	
A10	C18PMH-PEG	70	475	650	14.9	^h	Folate	<i>In vivo</i> targeted tumor imaging ¹⁴²
A11	PS-PMAA	68	365	486	62.1	—	No	<i>In vitro</i> cell imaging ¹⁴³
A10		—	489	610	22.3	—	No	
A6	PLGA/PLGA-PEG-folate	202 ^c	515	670	30	—	Folate	<i>In vitro</i> cell imaging ¹⁴¹
		177 ^d	515	670	17	—		
A12	In situ polymerization	120	—	612	—	—	No	<i>In vitro</i> cell imaging ^{146–148,150}
A13		303	470	607	—	—	No	
A14		472	—	578	—	—	No	
A15		25	410	518	40	—	No	

^a The sizes of nanoparticles were determined by DLS unless otherwise specified. ^b The sizes of nanoparticles were determined by TEM. ^c A6-PLGA nanoparticles with eccentric loading of AIE fluorogens. ^d A6-PLGA nanoparticles with homogeneous loading of AIE fluorogens. ^e No obvious precipitation upon storage at 4 °C for 3 months. ^f Same size after incubation in PBS buffer at 37 °C for 10 days. ^g No obvious precipitation upon storage at 4 °C for months. ^h Stable size in PBS buffer and in water over a wide pH range of 4–10.

As an example, fluorogen A2 was synthesized by attaching two TPE units to a well-known red emitter, 2-{2,6-bis[(*E*)-4-(diphenylamino)styryl]-4*H*-pyran-4-ylidene}malononitrile, which has both TITC and ACQ features.¹²⁷ A2 shows typical TITC and AIE properties, and the fluorescence of A2-loaded nanoparticles is almost linearly intensified as the amount of encapsulated A2 increases within the studied concentration range (Fig. 15b). The high brightness of AIE fluorogens in the solid state and the distinct feature that AIE fluorogens become stronger emitters at higher concentrations make them promising candidates for the development of organic nanoparticles. So far, several strategies, such as polymer conjugation, polymer matrix encapsulation and *in situ* polymerization, have been used to form AIE nanoparticles for *in vitro* and *in vivo* applications. The absorption and emission maxima, the sizes and quantum yields of the reported polymer encapsulated AIE nanoparticles together with their matrices and applications are summarized in Table 2.

3.2.1. Chitosan nanoparticles. Direct conjugation of AIE fluorogens to biocompatible polymers (*e.g.*, chitosan) could yield AIE-polymer conjugates that could be self-assembled into nanoparticles.^{128,129} For example, Tang and co-workers reported a TPE-chitosan conjugate through coupling between an isothiocyanate-containing TPE derivative and chitosan.¹²⁸ The resulted A3-chitosan conjugate shows typical AIE behavior and the fluorescence of the conjugate is intensified with the increased amount of A3 attached. The high labeling rate is

beneficial to afford highly fluorescent conjugates, which is an obstacle encountered by traditional ACQ fluorogens.¹³⁰ The A3-chitosan conjugates were able to be internalized into HeLa cells and trace the cells for 15 passages (Fig. 16). The extraordinary long-term cell tracing ability was attributed to the fact that the internalized AIE aggregates were preserved in one cell, instead of being averaged to two daughter cells in each cell division cycle. Meanwhile, Wei and co-workers reported the synthesis of TPE derivative-decorated amphiphilic A4-chitosan conjugates through coupling between the aldehyde groups of A4 and the amine groups of chitosan in an alkaline environment in the presence of NaBH₄.¹²⁹ The A4-chitosan conjugates were able to self-assemble into nanoparticles with sizes in the range of 200 to 400 nm in water. The obtained nanoparticles showed low cytotoxicity and efficient living cell internalization.

As compared to many reported fluorescent dye-polymer conjugates, conjugation of AIE fluorogens to polymers yielded highly fluorescent polymers. It is also interesting to note that the polymer fluorescence will intensify with the increased amount of AIE fluorogens conjugated to the polymer. AIE fluorogens bearing aldehyde groups could be conjugated to natural polysaccharides, chitosan, *etc.*, to afford self-assembled nanoparticles with good living cell internalization efficiency and excellent biocompatibility for long-term cell tracing.¹²⁸ Further development of FR/NIR AIE fluorogens will likely yield highly fluorescent biocompatible polymers for practical applications. Despite a useful strategy, it






Fig. 16 Chemical structures of **A3** and **A4**. Fluorescent images of HeLa cells stained by **A3**–chitosan conjugates at different passages (P) (reprinted with permission from ref. 128, Copyright 2013 American Chemical Society).

requires specific modification of each AIE fluorogen prior to polymer conjugation and nanoparticle formation.

3.2.2. DSPE-PEG nanoparticles. Besides chemical conjugation, direct encapsulation of hydrophobic AIE fluorogens using biocompatible polymers offers a more direct and feasible strategy for AIE nanoparticle synthesis. We recently developed a nanoprecipitation strategy using folate-functionalized 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-(polyethylene glycol) (DSPE-PEG₅₀₀₀-folate) as the encapsulation matrix. The folate density can be adjusted by varying the feed ratio of DSPE-PEG₅₀₀₀-folate to DSPE-PEG₂₀₀₀ for AIE nanoparticle preparation.¹³¹ The nanoparticles showed good selectivity between MCF-7 and NIH/3T3 cells due to the specific folate receptor-mediated endocytosis for MCF-7 cells and the presence of long PEG chains which suppressed nonspecific cellular uptake of the nanoparticles. Later, He and co-workers reported the fabrication of DSPE-PEG encapsulated **A5** nanoparticles with an emission maximum at 577 nm for *in vivo* sentinel lymph node (SLN) mapping.²⁰ The average size of the nanoparticles is less than 30 nm by TEM (Fig. 17a). When DSPE-PEG-maleimide was used as the matrix, feasible functionalization with thiol-RGD was realized to endow nanoparticles with tumor targeting ability. The RGD-functionalized **A5** nanoparticles were also used for targeted xenografted tumor imaging in mice. However, the signal-to-background ratio is not very satisfactory, as the nanoparticle fluorescence is orange (Fig. 16b).

In 2013, Tang *et al.* reported the synthesis of an FR/NIR emissive AIE fluorogen *via* the AIE + AIE approach. **A6** was obtained by conjugating TPE with an AIE active molecule of 2,3-bis[4-(diphenylamino)phenyl]fumaronitrile.¹³² Such conjugation not only maintained the AIE characteristics of the molecule, but also led to FR/NIR emission for **A6**. Encapsulation of **A6** with




Fig. 17 Chemical structure of **A5** and (a) TEM image of the **A5** nanoparticles and (b) *in vivo* fluorescence image of mice bearing subcutaneous tumor xenografts upon injection of **A5** nanoparticles (top) and RGD-**A5** nanoparticles (bottom) (reprinted with permission from ref. 20, Copyright 2011 Elsevier B.V.).

a mixture of DSPE-PEG and DSPE-PEG-NH₂ yielded **A6**-based nanoparticles with a uniform average size of ~30 nm in water and a fluorescence quantum yield of 24%. Due to their small and uniform sizes, these AIE nanoparticles were also termed AIE dots. The dots showed absorption and emission maxima at 511 and 671 nm. Further functionalization of the dots with Tat (RKKRRQRRRC) peptide afforded Tat-AIE dots that are over 10-fold brighter than the commercial Qtracker[®] 655 in single nanoparticle imaging analysis. It is noteworthy that the notorious blinking behavior of QDs is absent in these Tat-AIE dots. *In vitro* and *in vivo* studies suggested that Tat-AIE dots were






Fig. 18 Representative *in vivo* fluorescence imaging of the mouse subcutaneously injected with 1×10^6 of C6 glioma cells labeled with (a) Tat-A6 dots and (b) Qtracker[®] 655. The images were taken on designated days post cell injection. ROI: region of interest (reprinted with permission from ref. 132, Copyright 2013 Nature Publishing Group).

able to trace MCF-7 cells up to 12 passages and C6 cells up to 21 days. Upon subcutaneous injection in living mice, the fluorescence from cells treated with Tat-A6 dots remained very high at day 12 post-injection while that from cells treated with Qtracker[®] 655 vanished at day 7 (Fig. 18). The high quantum yield and FR/NIR emission of A6 dots ensured *in vivo* tracing of the labeled cells with high contrast. The A6 dots have also been reported to be an effective contrast agent for *in vivo* two photon fluorescence imaging.^{132,133}

The A6 dots together with their green fluorescent analogues have been further used to monitor the migration behaviors and interactions between two populations of cancer cells.¹³⁴ The A6 and A7 AIE dots were prepared by nanoprecipitation using DSPE-PEG-maleimide as the polymer matrix, followed by surface functionalization with thiol-decorated Tat peptide through the thiol-maleimide coupling reaction. Both dots show large Stokes shifts and have an intense absorption intersection at 455 nm with a high extinction coefficient of $\sim 4 \times 10^7 \text{ M}^{-1} \text{ cm}^{-1}$. Due to their distinct emission peaks at 539 and 670 nm with minimal spectral overlap (Fig. 19), the Tat functionalized A6 and A7 dots were further employed to label and track the interaction between two groups of highly motile HT1080 cells. *Ex vivo* imaging of the lung tissues from the mouse injected




Fig. 19 Chemical structure of A7. The absorption (solid line) and emission (dashed line) spectra of A6 (red) and A7 (green) dots in water (reprinted with permission from ref. 134, Copyright 2013 American Chemical Society).

with the mixture of cells separately labeled with these dots revealed no fluorescence signal interference. Dual-modality AIE dots with both fluorescent and magnetic properties were further obtained through surface attachment of diethylenetriaminepentaacetic (DTPA)-gadolinium(III) on A6 Tat-AIE dots, which allowed accurate analysis of the biodistribution of labeled cells through gadolinium(III) ion quantification.¹³⁵ The excellent performance of these AIE dots makes it possible to monitor cell interaction and migration during metastasis using a mouse model.

The versatile surface functionalities make DSPE-PEG encapsulated AIE dots suitable for diverse bioconjugation. Based on




Fig. 20 Chemical structures of A8 and A9. (a) Plot of PL intensity versus water fraction in the THF-water mixture of fluorogen A8. (b) Confocal images of C6 cells labeled with A8 NLS-AIE dots (reprinted with permission from ref. 136, Copyright 2013 Wiley-VCH).






Fig. 21 3D reconstructed two-photon fluorescence images of blood vessels in (a) brain (0–425 μm), (b) bone marrow (0–108 μm), and (c) mouse ear skin (0–132 μm) from the mouse injected with **A7** AIE dots. All images share the same scale bar of 20 μm (reprinted with permission from ref. 137, Copyright 2013 Wiley-VCH).

the TICT + AIE strategy, Tang and co-workers synthesized two new fluorogens (**A8** and **A9**) that showed both TICT and AIE features (Fig. 20a).¹³⁶ Conjugation of **A8** and **A9** AIE dots with a nuclear localization signal (NLS) Tat sequence (YGRKKRRQRRRC) yielded NLS Tat-AIE dots, which exhibited certain permeability to cellular nucleus (Fig. 20b). It is noteworthy that the **A8** and **A9** AIE dots have fluorescence quantum yields as high as 55% and 67% in water, respectively, ensuring high contrast in cell imaging. The ultrahigh brightness, good photostability and low cytotoxicity of these NLS Tat-AIE dots enable them to trace MCF-7 cancer cells up to 7 days.

In addition to cell tracking, the bright AIE dots have also been used for *in vivo* two-photon fluorescence imaging of intravital blood vessels.¹³⁷ The **A7** dots have a small size of ~ 33 nm with a high quantum yield of 62%, a large two photon absorption action cross section value of 6.3×10^4 GM (810 nm) based on dot concentration, and low *in vivo* toxicity. Upon intravenous injection, the major blood vessels, the smaller capillaries in the pia matter as well as the microvasculature deep in the brain that lies beyond the pia mater were clearly visualized with imaging depth up to 500 μm and resolution up to a few micrometers (Fig. 21a). The vascular systems in skull bone marrow and skin were also imaged to demonstrate the *in vivo* two photon fluorescence imaging ability of AIE dots (Fig. 21b and c). Similar results have also been observed for DSPE-PEG encapsulated **A6** dots,¹³³ which indicate that AIE dots with good photostability provide a novel platform to visualize blood vessels *in vivo* for better understanding of biological processes, such as angiogenesis and vascular leakage. These studies also offered fundamental guidelines for future design of novel AIE probes with two-photon excited fluorescence imaging capability for potential clinical translation.

One of the intrinsic limitations of the currently available AIE dots is their broad emission spectra, which limit their application in multiplexing. This is due to the large conformational difference in the ground state and the first singlet excited state as well as the abundant vibration energy levels of the torsional molecule structures for AIE fluorogens.¹³⁸ Due to the good spectral overlap between **A6** emission and NIR775 absorption, co-encapsulation of **A6** and NIR775 in DSPE-PEG yielded fluorescent nanoparticles with narrow NIR emission.¹³⁹

With increasing NIR775 mass ratios from 0.5% to 1.5%, the **A6** emission from 550 to 750 nm was greatly quenched while the NIR775 emission band from 750 to 900 nm increased gradually upon excitation of **A6** at 510 nm. A further increase in the NIR775 concentration up to 4% resulted in reduced NIR emission intensity caused by self-quenching of NIR775. With 1.5% mass ratio in the feed, the emission intensity of NIR775 upon excitation at 510 nm was ~ 47 -fold higher than that upon direct excitation of NIR775 at 760 nm. Additionally, the **A6**/NIR775 nanoparticles showed a band width of only 20 nm with a fluorescence quantum yield of $\sim 7\%$. *In vivo* imaging study revealed that the intravenously injected **A6**/NIR775 nanoparticles were able to provide 5.2-fold higher fluorescence contrast in live animals upon excitation at 523 nm vs. 704 nm. As a result, the FRET strategy offers new opportunities to synthesize AIE dots with high brightness and narrow emission, simply by selecting suitable donor-acceptor pairs.

So far, most of the AIE nanoparticles were fabricated using DSPE-PEG as the matrix due to their simple process. These nanoparticles, especially those based on **A6**, generally have a much smaller size (30–50 nm) as compared to those obtained *via* AIE fluorogen-polymer conjugate self-assembly. Due to their small size and very good photo- and colloidal stability, these nanoparticles have been widely used for *in vitro* and *in vivo* cell tracing,^{126–129} targeted tumor imaging¹⁴² and *in vivo* SLN mapping (Table 2).²⁴ Of significant interest is Tat functionalized and DSPE-PEG encapsulated **A6** dots, which showed superior performance over commercial Qtracker[®] 655 in both *in vitro* and *in vivo* cancer cell tracing. As most FR/NIR AIE fluorogens contain donor-acceptor structures, the reported AIE dots are also two-photon active, enabling them to be used for two-photon fluorescence imaging with a higher penetration depth than the commonly used one-photon fluorescence imaging.^{133,137} The reported AIE/NIR dye co-encapsulation strategy successfully addressed the disadvantage of the broad emission spectra for AIE dots,¹³⁹ which opens new opportunities for potential AIE dot based multiplexing.

3.2.3. PLGA nanoparticles. Based on the RIR mechanism of AIE fluorogens, it was hypothesized that the differences in the packing of AIE fluorogens in nanoparticles could affect their quantum yields and brightness.¹⁴⁰ Both eccentrically and



homogeneously loaded **A7** nanoparticles were prepared through single emulsion using a mixture of PLGA/PLGA-PEG-folate as the encapsulation matrix in the presence of different amounts of polyvinyl alcohol (PVA) as the emulsifier.¹⁴¹ With 0.5% PVA solution, **A7** fluorogens were found to be eccentrically localized at one side of nanoparticles due to evaporation induced phase separation between **A7** and the PLGA matrix. When the emulsifier was changed to 2.5%, **A7** fluorogens were almost homogeneously distributed in the PLGA matrix, indicating that the high PVA concentration helped to homogenize **A7** molecules within the PLGA matrix. For the same feed amount of **A7**, the quantum yield of eccentrically loaded PLGA nanoparticles (size of ~ 202 nm) is 30%, which is ~ 1.8 -fold higher than that of the homogeneously loaded nanoparticles (size of ~ 177 nm). This could be attributed to the fact that the eccentric pattern resulted in a more compact aggregation of the AIE fluorogens that could more effectively restrict the intramolecular rotation of phenyl rings and populate the radiative decay channels. The study thus offered new insight into the development of bright AIE nanoparticles by controlling internal architectures of the loaded fluorogens through careful selection of polymer matrices.

3.2.4. Other amphiphilic block co-polymer based nanoparticles. By taking advantage of self-aggregation of hydrophobic AIE fluorogens in aqueous media, Zhang and co-workers synthesized **A10** based polymeric nanoparticles through a two-step method for targeted cell imaging.¹⁴² The hydrophobic **A10** was dissolved in THF and the solution was quickly mixed with water under vigorous stirring to yield bare nanoparticle suspension, which was followed by addition of an aqueous solution of amphipathic poly(maleic anhydride-*alt*-1-octadecene)-polyethylene glycol (C18PMH-PEG) under ultrasonication to render the **A10** nanoparticles with surface coating (Fig. 22). The nanoparticles have a quantum yield of 14.9% with an average size of ~ 70 nm in water. The nanoparticles have excitation and emission maxima at 475 and 650 nm, respectively, with low cytotoxicity and robust photostability. C18PMH-PEG-folate was also used for surface coating to yield nanoparticles with abundant folate for *in vitro* targeted KB cell imaging and *in vivo*

tumor imaging. These nanoparticles have a blood circulation half-life of ~ 3 h and could preferentially accumulate in the tumor and liver of the mice.

To further enhance the fluorescence of AIE nanoparticles, Jen and co-workers demonstrated an elegant FRET strategy, and showed that the selection of amphiphilic encapsulation matrices could affect the quantum yields of the final AIE nanoparticles.¹⁴³ Three block copolymers, including poly(ϵ -caprolactone)-*b*-poly(ethylene glycol) (PCL-PEG), PS-PEG, and poly(styrene)-*b*-poly(methacrylic acid) (PS-PMAA), have been used to encapsulate two AIE fluorogens: red emissive **A10** and green emissive **A11**. Both PS-PMAA and PS-PEG encapsulated **A11** nanoparticles showed higher fluorescence quantum yields and smaller sizes than PCL-PEG encapsulated nanoparticles at the same emitter loading ratios. The average sizes of PS-PMAA encapsulated nanoparticles were found to increase from ~ 61 to ~ 68 nm upon increasing **A11** loading ratio from 0% to 20%, while the sizes of PS-PEG and PCL-PEG nanoparticles were in the range of 72–90 and 67–91 nm, respectively. The PS-PMAA nanoparticles gave the highest quantum yields of 62.1% for **A11** (20% loading ratio) and 22.3% for **A10** (5% loading ratio) among nanoparticles prepared using the three encapsulation matrices. For **A11** at 20% loading ratio, the longer lifetimes for PS-PMAA (8.41 ns) and PS-PEG (7.22 ns) nanoparticles than that for the PCL-PEG nanoparticles (4.83 ns) suggest that the PS core is more efficient in promoting radiative decay of AIE fluorogens. Further co-encapsulation of **A10** and **A11** into PS-PMAA yielded FRET nanoparticles with **A11** as the energy donor and **A10** as the




Fig. 22 Chemical structure of **A10** and schematic illustration of the synthesis of **A10** nanoparticles coated with C18PMH-PEG and C18PMH-PEG-folate (reprinted with permission from ref. 142, Copyright 2012 Elsevier B.V.).




Fig. 23 Chemical structure of **A11**. Confocal images of RAW cells incubated with PS-PMAA encapsulated (a) **A11** nanoparticles, (b) **A10** nanoparticles and (c and d) **A10/A11** co-loaded nanoparticles. The images from the left column were obtained using the green fluorescence channel while the images from the right column were obtained using the red fluorescence channel under the same experimental conditions (reprinted with permission from ref. 143, Copyright 2010 Wiley-VCH).



energy acceptor. Efficient energy transfer (99%) and amplification of **A10** emission (~ 8 -fold higher than **A10** alone) were achieved. Upon incubation with RAW cells, intense green fluorescence is observed from cells treated with **A11** nanoparticles while almost no red fluorescence is detectable from cells incubated with **A10** nanoparticles (Fig. 23a and b). Under the same experimental conditions, for **A10/A11** co-encapsulated nanoparticle treated cells, the green fluorescence is greatly suppressed while intense red fluorescence is observed (Fig. 23c and d). In addition to the AIE–AIE donor–acceptor pairs, Liu and co-workers also reported that the fluorescence from **A2** nanoparticles could be further intensified by over 5-fold *via* FRET from **CP3** to **A2** once they are co-encapsulated into bovine serum albumin (BSA) nanoparticles.¹⁴⁴ These results clearly indicate that FRET is an efficient strategy to further increase the brightness of AIE nanoparticles.

The studies in different groups clearly revealed that the structure and amphiphilicity of the block copolymers have a significant impact on the stability and brightness of the AIE nanoparticles. The lengths of the hydrophobic and hydrophilic components not only affect the nanoparticle size, but also their contact with AIE fluorogens. As compared to DSPE-PEG, the customized block copolymers offer tunable hydrophobic segments, which can entangle with the AIE fluorogens rather than through physical adsorption to yield more stable nanoparticles. As compared to the AIE fluorogen–polymer conjugate self-assembly, the encapsulation strategy also promotes well-controlled feeding ratio of AIE fluorogens to polymer matrices to yield optimized quantum yields in water. Amphiphilic polymers with better biocompatibility and different functional groups are expected to offer more choices for AIE nanoparticle fabrication.

3.2.5. *In situ* polymerized nanoparticles. *In situ* polymerization is an effective methodology to covalently incorporate

reactive AIE fluorogens into polymeric nanoparticles.¹⁴⁵ Different from physical encapsulation, *in situ* polymerization could yield polymeric nanoparticles with AIE fluorogens covalently bonded, which have advantages in terms of compact structure without dye leakage or surface coating detachment in harsh biological environments. Wei and co-workers reported the synthesis of AIE nanoparticles containing cross-linkable AIE fluorogens (**A12**, **A13** and **A14**) through reversible addition-fragmentation chain transfer (RAFT) polymerization,¹⁴⁶ ring-opening polymerization¹⁴⁷ and emulsion polymerization.¹⁴⁸ The obtained nanoparticles showed low cytotoxicity and desired internalization efficiency upon incubation with A549 cells, suggesting their potential use in fluorescence imaging. Taking **A12** as an example, upon RAFT polymerization of poly(ethylene glycol) monomethyl ether methacrylate (PEGMA) and **A12**, the yielded polymers were amphiphilic and were able to self-assemble into nanoparticles in water. The TEM image suggested that the polymerized conjugates formed nanoparticles with a spherical shape (Fig. 24a). DLS results suggested that the sizes of the obtained **A12** nanoparticles decreased from 290 nm to 120 nm with the increased degree of polymerization of PEGMA from 20 to 40. However, the emission maximum in water remained at 612 nm, which was size independent. In another example, **A13** bearing two reactive primary amine groups was used to react with 4,4'-oxydiphthalic anhydride *via* anhydride ring-opening polymerization to yield AIE nanoparticles in water. The nanoparticles had an average size of ~ 303 nm by DLS with an emission maximum at 607 nm. The group further reported the synthesis of AIE nanoparticles with core-shell structures through emulsion polymerization of **A14**, styrene and acrylic acid in the presence of sodium dodecyl benzene sulfonate as the emulsifier. During polymerization, **A14** molecules aggregated in the hydrophobic core of polystyrene,




Fig. 24 Chemical structures of **A12**, **A13** and **A14**. TEM images of (a) **A12**, (b) **A13** and (c) **A14** nanoparticles prepared from RAFT, ring-opening polymerization and emulsion polymerization (reprinted with permission from ref. 146–148, Copyright 2013, 2014 and 2014 Royal Society of Chemistry).






Fig. 25 Synthetic route to the representative **A15**-containing amphiphilic polymer (reprinted with permission from ref. 150, Copyright 2012 Royal Society of Chemistry).

while the hydrophilic poly(acrylic acid) served as a hydrophilic shell. The obtained **A14** nanoparticles showed an average diameter of ~ 472 nm in water by DLS with an emission maximum at 578 nm. It is noteworthy that all these nanoparticles were found to have spherical shapes with sizes in the range of 100 to 200 nm under TEM (Fig. 24).¹⁴⁹

Tian and co-workers also reported the synthesis of amphiphilic polymers with AIE fluorogens at the side chain to facilitate self-assembly into nanoparticles for fluorescence imaging.¹⁵⁰ The amphiphilic **A15**-containing polymers were obtained through polymerization among monomeric **A15**, *N*-(2-hydroxypropyl) methacrylamide (HPMA), [2-(methacryloyloxy)ethyl]trimethylammonium chloride (MATMA), and/or 2,2,2-trifluoroethyl methacrylate (TFEMA), as shown in Fig. 25. In water, the copolymers without TFEMA segments self-assembled into nanoparticles with average sizes of 7–9 nm, while the TFEMA-containing polymers led to AIE nanoparticles with average sizes of 21–25 nm by DLS. In the absence of TFEMA, the quantum yields of **A15** nanoparticles were increased from 2% to 10% when the molar percentage of **A15** in the copolymers was increased from 1 to 12 mol%. The presence of hydrophobic TFEMA in the polymer backbone significantly improved the quantum yield to 40%, once 1 mol% of **A15** and 42.5 mol% of TFEMA were used for polymerization. This was due to the enhanced hydrophobicity of the TFEMA-containing polymer, which promoted compact aggregation of **A15** in the core. Due to the presence of ¹⁹F in TFEMA, the AIE nanoparticles have great potential in dual-modality imaging applications. As such, *in situ* polymerization represents a general strategy to customize AIE nanoparticles with versatile functionalities through incorporation of desired reactive monomers.

AIE fluorogens with polymerizable functional groups (*e.g.* vinyl or bis-amine groups) could be used as monomers to yield AIE nanoparticles with large sizes in water (200–400 nm) through *in situ* polymerization with other encapsulation matrix precursors. The strategy is able to yield very stable nanoparticles

and the content of AIE fluorogens in each nanoparticle could be fine-tuned by adjusting the AIE monomers in the feed. However, multiple synthetic steps are required for modifying each AIE fluorogen before polymerization, which adds complexity and cost to the AIE nanoparticle production. The size distribution and the surface of these nanoparticles also require further optimization before they could be used for more specific applications.

4. Photoacoustic imaging

Although fluorescence imaging techniques have shown high resolution and sensitivity, they lack good spatial resolution in *in vivo* applications due to limited penetration depth in animals. One solution is to develop multi-modal imaging probes through incorporation of other imaging modalities (such as MRI and radioactive agents) into the organic fluorescent probes. The alternative strategy is to explore new imaging modalities, such as photoacoustic (PA) imaging. Recently, PA imaging technology has emerged as a novel method that allows the visualization of optical reporter agents with never-seen-before performance. In particular, multispectral PA technology endows highly specific molecular imaging through several millimetres to centimetres of tissue with resolutions in the 20–200 μ m range.^{151,152} The mechanism of PA imaging is based on the generation of acoustic waves following the absorption of light pulses of ultrashort duration. After the tissue is illuminated with light pulses, the fast absorption of light pulses by PA contrast agents in tissue enables the absorbed energy to undergo a thermoelastic expansion that emits mechanical waves at ultrasonic frequencies. These waves can subsequently be detected by acoustic detectors close to the illuminated tissue, which is followed by reconstruction of the images of absorbed energy in analogy to the formation of ultrasound images using appropriate mathematical methods.^{153,154}



To date, the most widely used PA contrast agents are gold nanomaterials including nanorods, nanocages and nanoshells.^{155–158} In addition, several reports have also utilized carbonous nanomaterials (such as carbon nanotubes and polyhydroxy fullerenes).^{159,160} The recent research interest in PA probe design has been extended to NIR dyes and organic nanoparticles due to their benign biocompatibility.^{161–165} As large NIR absorption coefficients and high nonradiative quantum yields are key features for organic materials to yield strong PA signals, efforts have been made to look for or design organic emitters with long wavelength absorption and maximized non-radiative pathways to achieve high non-radiative quantum yields for PA imaging.

Recently, CPs have emerged as a new class of organic agents for PA imaging. Initial studies were focused on polypyrrole (PPy) as the PA agent. PPy is a non-soluble CP with intense NIR absorption that has been widely used for organic electronics^{166,167} and biological applications.^{168–170} In 2013, Dai and co-workers reported the application of PPy nanoparticles (CP14) for brain vascular imaging in a living mouse model. The PPy nanoparticles were synthesized by aqueous phase polymerization using PVA as the stabilizing agent and FeCl₃ as an oxidation catalyst.¹⁷¹ Due to the surface PVA molecules and their small size (diameter of ~46 nm in water), the PPy nanoparticles were well dispersed in water with strong absorption in the 700–900 nm region. Upon illumination with an 808 nm pulse laser, the PA signals increased linearly with increasing concentrations of nanoparticles in water. Intravenous administration of PPy nanoparticles allowed imaging of the cerebral cortex of the mouse brain vasculature with greater clarity than the intrinsic signal from hemoglobin in blood. At 1 h post-injection,

the PA signal remained essentially intense, indicating that a sufficient amount of PPy nanoparticles has long-circulating ability in blood (Fig. 26). Moreover, no acute toxicity to the vital organs (e.g., heart, liver, lung, spleen and kidney) was observed at 15 day post-injection, suggesting good biocompatibility of the PPy-PVA nanoparticles.

Although PPy nanoparticles have shown strong PA signals, PPy is not soluble in almost any organic solvent with very poor chemical processability. In addition, the PPy nanoparticles synthesized from *in situ* polymerization do not allow feasible surface modification as there is no surface functional group. To overcome this limitation, Liu and co-workers developed processable CP15 with NIR absorption and fabricated DSPE-PEG encapsulated CP15 nanoparticles through nanoprecipitation.¹⁷² In the molecular structure of CP15, the electron-deficient thiadiazoloquinoxaline acted as a good electron acceptor to ensure small band gap of the polymer with long wavelength absorption. The obtained CP15 nanoparticles have sizes of ~50 nm under TEM, which showed strong absorbance in the NIR region with a high non-radiative quantum yield of almost 100%, suggesting that most of the excited excitons returned to the ground state *via* the non-radiative decay pathway. When CP15 nanoparticles were continuously irradiated with a fixed laser fluence of 15 mJ cm⁻², no significant absorbance change was observed in 6 min. This compared favourably with Au nanorods, which showed an ~60% decrease in absorbance within 5 seconds under the same laser irradiation. *In vivo* rat brain vascular imaging highlighted the good PA contrast of CP15 nanoparticles in blood, revealing that the PA intensity was improved by ~3-fold after nanoparticle injection as compared to the intrinsic signal upon excitation at 808 nm. Overall, the intense NIR absorption, high non-radiative quantum yield, excellent photostability and low cytotoxicity of CP15 nanoparticles highlight the great potential of processable CP nanoparticles for *in vivo* PA imaging. Further encapsulation of CP15 with DSPE-PEG-folate as the matrix yielded CP based PA probes for targeted tumor imaging and direct visualization of nanoparticle biodistribution in different organs.

Rao and co-workers further developed activatable photoacoustic probes using CP16 for *in vitro* and *in vivo* imaging of reactive oxygen species (ROS).¹⁷³ CP16 and CP17 nanoparticles were prepared through nanoprecipitation assisted by 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine, resulting in CP nanoparticles with average diameters of ~40 nm by TEM. As compared to CP17 nanoparticles, the narrower PA spectra and five-fold greater PA amplitude make CP16 nanoparticles a better PA imaging probe. On a per mass basis, the PA signal of CP16 nanoparticles in living mice was ~4.0 and 5.8 times higher than that of single-walled carbon nanotubes and gold nanorods upon excitation at 700 nm. Through co-precipitation of CP16 nanoparticles with IR775, the nanoparticles showed three maxima at 700, 735 and 820 nm in the photoacoustic spectrum with nearly the same amplitude (Fig. 27b). In the presence of ONOO⁻ and ClO⁻, the photoacoustic peaks at 735 nm and 820 nm decreased significantly, while the peak at 700 nm remained nearly the same. The obvious change for the




Fig. 26 Chemical structures of CP14 and CP15. (a) Photograph of the mouse brain obtained before the data acquisition for PAT. Non-invasive PAT imaging of a mouse brain *in vivo* at 5 min (b) and 60 min (c) post-injection of CP14 nanoparticles upon excitation at 808 nm (reprinted with permission from ref. 171, Copyright 2013 Royal Society of Chemistry).






Fig. 27 Chemical structures of **CP16** and **CP17**. (a) Schematic illustration of the **CP16**/IR775 nanoparticles for ROS detection. (b) Representative photoacoustic spectra of **CP16**/IR775 nanoparticles in the absence and presence of ROS (reprinted with permission from ref. 173, Copyright 2014 Nature Publishing Group).

peak at 820 nm was attributed to the ROS-mediated rapid oxidative decomposition of IR775. As a result, the dual-peak ratiometric changes (PA_{700}/PA_{800}) provided a clear signal for $ONOO^-$ and ClO^- detection. The successful demonstration of ratiometric PA imaging of ROS in living mice offers new opportunities for advanced PA molecular imaging, which has great potential in preclinical investigation and clinical translation of physiological and pathological processes.

Although at the initial stage, NIR absorbing CPs have been demonstrated to be a new class of promising agents for PA imaging with high signal output and good photostability. The chemical stability (e.g., stable PA signal in the presence of ROS) also inspires new research directions in CP nanoparticle based PA molecular imaging. As compared to traditional PA imaging agents with large NIR absorption (e.g., gold nanorods, gold cages), the feasible polymer encapsulation procedures can easily endow the CP nanoparticles with different surface functionalities for targeted imaging. It is also important to note that simultaneous fluorescence and PA signals could be generated from single CP based nanoparticles, which is useful for self-validation in target sensing and imaging.¹⁷³

5. Concluding remarks and perspectives

In this review, recent progress of polymer-encapsulated organic nanoparticles using CPs and AIE fluorogens as the emitters for fluorescence and photoacoustic imaging has been summarized.

The polymer encapsulation strategy has been proved to be simple and effective in quickly transforming organic soluble molecules into aqueous media, and for fast screening of them for various biological applications. For fluorescence imaging, the brightness, stability, toxicity, size and biodegradability (or body clearance) of the nanoparticles are of major concern. Strategies such as incorporating bulky groups into the polymer backbone and side chains, introducing moieties to induce intramolecular and intermolecular energy transfer and controlling the polymer self-assembly in aggregates are effective in reducing aggregation caused quenching of CP nanoparticles. In addition, recent advances in the development of AIE fluorogens show great potential in constructing highly fluorescent nanoparticles as they take advantage of the natural aggregation process to increase the fluorescence. It has been reported that even for the same emitter, encapsulating them into different matrices can affect their molecular packing, aggregation, and distribution in the formed nanoparticles. Careful selection of the polymer matrix and fine-tuning the matrix to emitter ratio thus not only affect sizes, but also brightness and stability of the nanoparticles. Polymer encapsulated nanoparticles with sizes from a few to several hundreds of nanometers have been reported and versatile surface functional groups have been customized to cater to specific imaging tasks, such as organelle imaging, targeted *in vitro* and *in vivo* tumor imaging, cancer cell tracing, blood vessel imaging, and even specific chemical and biomolecular species imaging. As shown in Table 3, single particle analysis for both CP and AIE nanoparticles reveals that they could be designed to have higher brightness than commercially



Table 3 Comparison of CP/AIE nanoparticles with other commercial and synthetic probes

NPs ^a	Size (nm)	Photostability	Physical/chemical stability	QY ^b	Fluorescence or PA signal	Ref.
CP6 PS-PEG	~15	Obvious fluorescence intermittence (blinking) for Qdot 565 and Alexa 488 and stable emission for CP6 nanoparticles (λ_{ex} = 488 nm, 1 mW)	Clear nanoparticle suspension after storage for 6 months	0.3	The single CP6 nanoparticle was ~30 times brighter than Qdot 565 and Alexa 488 upon excitation at 488 nm (4 mW)	71
Qdot 565	~15		—	0.3		
Alexa 488	~1		—	–0.5 0.9		
CP6 F127-SiO ₂	~12	Better photostability for F127-SiO ₂ nanoparticles than DSPE-PEG encapsulated ones	Stable emission in PBS buffer for 10 days	0.75	Single CP6 nanoparticle emitted ~3.4 fold more photons compared to each Qdot 655	119
CP6 DSPE-PEG	~30			0.40		
Qdot 655	—			0.15		
A6 DSPE-PEG	~30	Comparable photostability for A6 nanoparticles and Qtracker 655 upon excitation at 514 nm (2 mW)	Constant emission intensity in DMEM ^d for 9 days The emission dropped to 30% of its initial intensity in DMEM for 9 days	0.24	The single A6 nanoparticle was ~15-fold brighter than Qtracker 655 upon excitation at 488 nm	132
QD 655	—			0.15		
CP15 DSPE-PEG	~80			—		
Au NRs ^c	—	Upon continuous laser irradiation (15 mJ cm ^{–2}), no obvious change in absorbance was observed for CP15 nanoparticles in 6 minutes while a 60% decrease in absorbance at 800 nm was observed for Au NRs within 5 seconds	—	<0.01	An ~3-fold higher PA signal was observed in the brain vasculature upon CP15 nanoparticle injection (λ_{ex} = 808 nm)	172
CP16 DSPE-PEG	~40	Upon continuous laser irradiation at 9 mJ cm ^{–2} (700 nm), stable PA signal for CP16 nanoparticles and ~30% decrease of the PA signal for AuNRs within minutes	Stable PA signal in the presence of ROS	—		
Au NRs	—		—	—		
SWNTs ^e	—		—	—	CP16 nanoparticles in living mice showed ~4.0 and 5.8 times higher PA signal as compared to SWNTs and Au NRs on a per mass basis, upon excitation at 700 nm	173

^a NP: nanoparticle. ^b QY: quantum yield. ^c NR: nanorod. ^d DMEM: Dulbecco's modified Eagle's medium. ^e SWNT: single wall nanotube.

available polymer encapsulated quantum dots with a similar dimension. In addition, most of the reported polymer encapsulated organic nanoparticles show good physical stability, which has been further improved when chemical bonds are introduced to cross link the matrices and the emitters through either post-modification or *in situ* polymerization. Although the photostability of these nanoparticles is primarily determined by the emitters themselves, encapsulating them into the polymeric shells could obviously improve their stability against photobleaching. Additional advantages of these nanoparticles also include their excellent biocompatibility, good cellular permeability and low cytotoxicity, which have been demonstrated for almost all the reported CP and AIE nanoparticles *in vitro*. However, systematic investigation of their *in vivo* toxicity, biodistribution and biodegradability remains to be explored.

The recent discovery that CPs are active agents in PA imaging has significantly broadened their biomedical applications. This is also very exciting from the materials point of view. Despite the fact that great efforts have been made to develop highly fluorescent CPs for sensing and imaging applications, many existing CPs, such as those with FR/NIR absorption, are not very emissive, especially in the aggregated states. The emitters with strong NIR absorption and active non-radiative decay thus opened a new window for PA imaging. On a par mass basis, the PA signals from CP nanoparticles are even higher than those for the most widely used PA contrast agents,

such as Au nanorods and single-walled carbon nanotubes (Table 3). In addition, as non-radiative pathway is easily associated with heat generation, photoacoustic agents also have great potential to be used for photothermal therapy (PTT), which is a highly specific, low toxic and noninvasive strategy for cancer and tumor ablation.¹⁷⁴ Several CPs with FR/NIR absorption have also been demonstrated to be effective photothermal agents for imaging guided photothermal treatment of tumors.^{175,176} As the application of CPs in PA imaging and photothermal treatment is at the very early stage, the design principles for such nanoparticles and their operation mechanisms are not fully established. Nonetheless, the reported few examples have successfully demonstrated that CP based polymeric nanoparticles are very promising for deep *in vivo* tumor imaging and PTT with minimized side effects on normal tissues.^{171–176}

Future work of polymer encapsulated organic nanoparticles will be directed toward the development of smart and stimuli responsive imaging and therapy systems. Further development of CP and AIE fluorogens for biomedical applications will be mainly focused on the FR/NIR emitters with narrow band emission. Various signal amplification strategies, such as FRET and metal-enhanced fluorescence, could be used to further improve their brightness for fluorescence imaging. Similarly, further development of CP and AIE nanoparticle based multi-modal probes will be ideal for *in vitro* and *in vivo* imaging



applications, which will provide much higher sensitivity and accuracy with the complementary information provided by each imaging modality. In addition, when properly designed, a single emitter might be able to simultaneously show capabilities of fluorescence imaging, PA imaging and PTT effect, which will provide unprecedented simplicity in designing a single component based multimodality image-guided therapy agent. To fine-tune the size and fluorescence of such nanoparticles, more functionalized biodegradable polymeric shells will be developed to help deliver the imaging and therapeutic agents. For example, light, enzyme or pH responsive polymeric shells will be developed for targeted and responsive tumor imaging, while cross-linkable polymer matrices will be synthesized to further improve the stability and photostability of these nanoparticles. As most of the polymer matrices used in current studies are from commercial sources, more synthetic biocompatible polymers with adjustable lengths of the hydrophobic and hydrophilic domains are expected to lead to better control of the sizes and stability of the nanoparticles. The progress in molecular design, matrix selection, mechanism study, biological markers together with more detailed metabolic process and long term *in vivo* toxicity evaluation will provide more fundamental information and open new research opportunities for polymer encapsulated organic nanoparticles in biomedical applications and for potential clinical translation.

Acknowledgements

The authors are grateful to the A*STAR Joint Council Office and Institute of Materials Research and Engineering of Singapore (IMRE/12-8P1103, IMRE/13-8P1104), the Singapore National Research Foundation (R279-000-390-281), the Singapore Ministry of Defense (R279-000-340-232), and SMART (R279-000-378-592) for financial support.

Notes and references

- 1 F. Leblond, S. C. Davis, P. A. Valdés and B. W. Poque, *J. Photochem. Photobiol., B*, 2010, **98**, 77–94.
- 2 V. R. Kondepoti, H. M. Heise and J. Backhaus, *J. Anal. Bioanal. Chem.*, 2008, **390**, 125–139.
- 3 M. F. Kircher, S. S. Gambhir and J. Grimm, *Nat. Rev. Clin. Oncol.*, 2011, **8**, 677–688.
- 4 R. Y. Tsien, *Annu. Rev. Biochem.*, 1998, **67**, 509–544.
- 5 S. van de Linde, M. Heilemann and M. Sauer, *Annu. Rev. Phys. Chem.*, 2012, **63**, 519–540.
- 6 M. De, P. S. Ghosh and V. M. Rotello, *Adv. Mater.*, 2008, **20**, 4225–4241.
- 7 M. Chen and M. Yin, *Prog. Polym. Sci.*, 2014, **39**, 365–395.
- 8 A. M. Smith, H. Duan, A. M. Mohs and S. Nie, *Adv. Drug Delivery Rev.*, 2008, **60**, 1226–1240.
- 9 J. P. Wilcoxon and B. L. Abrams, *Chem. Soc. Rev.*, 2006, **35**, 1162–1194.
- 10 F. Wang and X. Liu, *Chem. Soc. Rev.*, 2009, **38**, 976–989.
- 11 S. N. Baker and G. A. Baker, *Angew. Chem., Int. Ed.*, 2010, **49**, 6726–6744.
- 12 L. Wang, W. Zhao and W. Tan, *Nano Res.*, 2008, **1**, 99–115.
- 13 G. Feng, J. Liang and B. Liu, *Macromol. Rapid Commun.*, 2013, **34**, 705–715.
- 14 Y. Liu, K. Ai, X. Cheng, L. Huo and L. H. Lu, *Adv. Funct. Mater.*, 2010, **20**, 951–956.
- 15 J. Yan, M. C. Estévez, J. E. Smith, K. Wang, X. He, L. Wang and W. Tan, *Nano Today*, 2007, **2**, 44–50.
- 16 *Advanced Fluorescence Reporters in Chemistry and Biology I*, ed. A. P. Demchenko, Springer, 2010.
- 17 S. Luo, E. Zhang, Y. Su, T. Cheng and C. Shi, *Biomaterials*, 2011, **32**, 7127–7138.
- 18 *Photophysics of Aromatic Molecules*, ed. J. B. Birks, Wiley-Interscience, London, 1970.
- 19 J. O. Escobedo, O. Rusin, S. Lim and R. M. Strongin, *Curr. Opin. Chem. Biol.*, 2010, **14**, 64–70.
- 20 D. Wang, J. Qian, S. He, J. S. Park, K.-S. Lee, S. Han and Y. Mu, *Biomaterials*, 2011, **32**, 5880–5888.
- 21 L. Wang, C. Y. Yang and W. Tan, *Nano Lett.*, 2005, **5**, 37–43.
- 22 L. Wang and W. H. Tan, *Nano Lett.*, 2006, **6**, 84–88.
- 23 Y. Hong, J. W. Y. Lam and B. Z. Tang, *Chem. Soc. Rev.*, 2011, **40**, 5361–5388.
- 24 *Conjugated Polymers: A Practical Guide to Synthesis*, ed. K. Müllen, J. R. Reynolds and T. Masuda, RSC, 2014.
- 25 D. T. McQuade, A. E. Pullen and T. M. Swager, *Chem. Rev.*, 2000, **100**, 2537–2574.
- 26 *Conjugated Polyelectrolytes: Fundamentals and Applications*, ed. B. Liu and G. C. Bazan, Wiley, 2013.
- 27 C. Zhu, L. Liu, Q. Yang, F. Lv and S. Wang, *Chem. Rev.*, 2012, **112**, 4687–4735.
- 28 B. Liu and G. C. Bazan, *Chem. Mater.*, 2004, **16**, 4467–4476.
- 29 K. Y. Pu and B. Liu, *Adv. Funct. Mater.*, 2011, **21**, 3408–3423.
- 30 A. Duarte, K. Y. Pu, B. Liu and G. C. Bazan, *Chem. Mater.*, 2011, **23**, 501–505.
- 31 C. Wu and D. T. Chiu, *Angew. Chem., Int. Ed.*, 2013, **52**, 3086–3109.
- 32 L. Feng, C. Zhu, H. Yuan, L. Liu, F. Lv and S. Wang, *Chem. Soc. Rev.*, 2013, **42**, 6620–6633.
- 33 K. Li and B. Liu, *J. Mater. Chem.*, 2012, **22**, 1257–1264.
- 34 K. Y. Pu and B. Liu, *Biosens. Bioelectron.*, 2009, **24**, 1067–1073.
- 35 Y. Wang and B. Liu, *Curr. Org. Chem.*, 2011, **15**, 446–464.
- 36 J. Pecher and S. Mecking, *Chem. Rev.*, 2010, **110**, 6260–6279.
- 37 D. Tuncel and H. V. Demir, *Nanoscale*, 2010, **2**, 484–494.
- 38 H. Jiang, P. Taranekekar, R. Reynolds and K. S. Schanze, *Angew. Chem., Int. Ed.*, 2009, **48**, 4300–4316.
- 39 K. Li, K. Y. Pu, L. P. Cai and B. Liu, *Chem. Mater.*, 2011, **23**, 2113–2119.
- 40 C. W. C. Szymanski, Z. Cain and J. McNeill, *J. Am. Chem. Soc.*, 2007, **129**, 12904–12905.
- 41 C. Szymanski, C. Wu, J. Hooper, M. A. Salazar, A. Perdomo, A. Dukes and J. McNeill, *J. Phys. Chem. B*, 2005, **109**, 8543–8546.
- 42 D. Ding, K. Li, B. Liu and B. Z. Tang, *Acc. Chem. Res.*, 2013, **46**, 2441–2453.



- 43 C. Kim, C. Favazza and L. V. Wang, *Chem. Rev.*, 2010, **110**, 2756–2782.
- 44 P. K. Kandel, L. P. Fernando, P. C. Ackroyd and K. A. Christensen, *Nanoscale*, 2011, **3**, 1037–1045.
- 45 Y. Liu and S. S. Feng, *J. Controlled Release*, 2011, **152**, e64–e65.
- 46 Z. Zhang and S. S. Feng, *Biomaterials*, 2006, **27**, 262–270.
- 47 M. J. Joralemon, S. Mcrae and T. Emrick, *Chem. Commun.*, 2010, **46**, 1377–1393.
- 48 G. Gaucher, R. H. Marchessault and J. C. Leroux, *J. Controlled Release*, 2010, **143**, 2–12.
- 49 J. Su, J. Chen, F. Zeng, Q. Chen, S. Wu and Z. Tong, *Polym. Bull.*, 2008, **61**, 425–434.
- 50 J. Chen, P. Zhang, G. Fang, P. Yi, X. Yu, X. Li, F. Zeng and S. Wu, *J. Phys. Chem. B*, 2011, **115**, 3354–3362.
- 51 J. Chen, F. Zeng, S. Wu, J. Su and Z. Tong, *Small*, 2009, **5**, 970–978.
- 52 S. Wang, G. Kim, Y.-E. K. Lee, H. J. Hah, M. Ethirajan, R. K. Pandey and R. Kopelman, *ACS Nano*, 2012, **6**, 6843–6851.
- 53 *Handbook on Applications of Ultrasound: Sonochemistry for Sustainability*, ed. D. Chen, S. K. Sharma and A. Mudhoo, CRC Press, 2011.
- 54 S. Hornig, T. Heinze, C. R. Becer and U. S. Schubert, *J. Mater. Chem.*, 2009, **19**, 3838–3840.
- 55 R. Jakubiak, C. J. Collison, W. C. Wan, L. J. Rothberg and B. R. Hsieh, *J. Phys. Chem. A*, 1999, **103**, 2394–2398.
- 56 H. Jiang, X. Y. Zhao and K. S. Schanze, *Langmuir*, 2007, **23**, 9481–9486.
- 57 S. W. Thomas III, G. D. Joly and T. M. Swager, *Chem. Rev.*, 2007, **107**, 1339–1386.
- 58 C. Qin, X. Wu, H. Tong and L. Wang, *J. Mater. Chem.*, 2010, **20**, 7957–7964.
- 59 S. Xiao, M. Nguyen, X. Gong, Y. Cao, H. Wu, D. Moses and A. J. Heeger, *Adv. Funct. Mater.*, 2003, **13**, 25–29.
- 60 J. Liu, G. Feng, D. Ding and B. Liu, *Polym. Chem.*, 2013, **4**, 4326–4334.
- 61 K. Y. Pu, K. Li and B. Liu, *Adv. Funct. Mater.*, 2010, **20**, 2770–2777.
- 62 Y. H. Jin, F. Ye, M. Zeigler, C. Wu and D. T. Chiu, *ACS Nano*, 2011, **5**, 1468–1475.
- 63 L. Yuan, W. Lin, K. Zheng, L. He and W. Huang, *Chem. Soc. Rev.*, 2013, **42**, 622–661.
- 64 S. Kim, C.-K. Lim, J. Na, Y.-D. Lee, K. Kim, K. Choi, J. F. Leary and I. C. Kwon, *Chem. Commun.*, 2010, **46**, 1617–1619.
- 65 J. Liu, J. Geng and B. Liu, *Chem. Commun.*, 2013, **49**, 1491–1493.
- 66 X. Y. Zhao, M. R. Pinto, L. M. Hardison, J. Mwaura, J. Müller, H. Jiang, D. Witker, V. D. Kleiman, J. R. Reynolds and K. S. Schanze, *Macromolecules*, 2006, **39**, 6355–6366.
- 67 Y.-H. Chan, F. Ye, M. E. Gallina, X. Zhang, Y. Jin, I.-C. Wu and D. T. Chiu, *J. Am. Chem. Soc.*, 2012, **134**, 7309–7312.
- 68 X. Zhang, J. Yu, Y. Rong, F. Ye, D. T. Chiu and K. Uvdal, *Chem. Sci.*, 2013, **4**, 2143–2151.
- 69 C. Wu, B. Bull, C. Szymanski, K. Christensen and J. McNeill, *ACS Nano*, 2008, **2**, 2415–2423.
- 70 K. Li, J. Pan, S. S. Feng, A. W. Wu, K. Y. Pu, Y. T. Liu and B. Liu, *Adv. Funct. Mater.*, 2009, **19**, 3535–3542.
- 71 C. Wu, T. Schneider, M. Zeigler, J. Yu, P. G. Schiro, D. R. Burnham, J. D. McNeill and D. T. Chiu, *J. Am. Chem. Soc.*, 2010, **132**, 15410–15417.
- 72 M. B. Zeigler, W. Sun, Y. Rong and D. T. Chiu, *J. Am. Chem. Soc.*, 2013, **135**, 11453–11455.
- 73 L. Brannon-Peppas and J. O. Blanchette, *Adv. Drug Delivery Rev.*, 2004, **56**, 1649–1659.
- 74 D. Klose, F. Siepmann, K. Elkharraraz and J. Siepmann, *Int. J. Pharm.*, 2008, **354**, 95–103.
- 75 F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton and V. Préat, *J. Controlled Release*, 2012, **161**, 505–522.
- 76 C. Wu, H. Peng, Y. Jiang and J. McNeill, *J. Phys. Chem. B*, 2006, **110**, 14148–14154.
- 77 K. Li, Y. T. Liu, K. Y. Pu, S. S. Feng, R. Y. Zhan and B. Liu, *Adv. Funct. Mater.*, 2011, **21**, 287–294.
- 78 B. Liu and G. C. Bazan, *J. Am. Chem. Soc.*, 2004, **126**, 1942–1943.
- 79 K.-Y. Pu and B. Liu, *Macromolecules*, 2008, **41**, 6636–6640.
- 80 D. Yu, Y. Zhang and B. Liu, *Macromolecules*, 2008, **41**, 4003–4011.
- 81 K. Li, R. Y. Zhan, S. S. Feng and B. Liu, *Anal. Chem.*, 2011, **83**, 2125–2132.
- 82 H. Xu, M. Y. Sha, E. Y. Wong, J. Uphoff, Y. Xu, J. A. Treadway, A. Truong, E. O. Brien, S. Asquith, M. Stubbins, N. K. Spurr, E. H. Lai and W. Mahoney, *Nucleic Acids Res.*, 2003, **31**, e43.
- 83 M. Liong, J. Lu, M. Kovochich, T. Xia, S. G. Ruehm, A. E. Nel, F. Tamanoi and J. L. Zink, *ACS Nano*, 2008, **2**, 889–896.
- 84 P. Howes, M. Green, A. Bowers, D. Parker, G. Varma, M. Kallumadil, M. Hughes, A. Warley, A. Brain and R. Botnar, *J. Am. Chem. Soc.*, 2010, **132**, 9833–9842.
- 85 B. Sun, M. J. Sun, Z. Gu, Q.-D. Shen, S.-J. Jiang, Y. Xu and Y. Wang, *Macromolecules*, 2010, **43**, 10348–10354.
- 86 K. Li, D. Ding, D. Huo, K. Y. Pu, N. N. P. Thao, Y. Hu, Z. Li and B. Liu, *Adv. Funct. Mater.*, 2012, **22**, 3107–3115.
- 87 X. Gao, L. Yang, J. A. Petros, F. F. Marshall, J. W. Simons and S. Nie, *Curr. Opin. Biotechnol.*, 2005, **16**, 63–72.
- 88 J. Geng, K. Li, K. Y. Pu, D. Ding and B. Liu, *Small*, 2012, **8**, 2421–2429.
- 89 T. Chen, M. X. Yang, X. J. Wang, L. H. Tan and H. Y. Chen, *J. Am. Chem. Soc.*, 2008, **130**, 11858–11859.
- 90 J. Yang, C. H. Lee, J. Park, S. Seo, E. K. Lim, Y. J. Song, J. S. Suh, H. G. Yong, Y. M. Huh and S. Haam, *J. Mater. Chem.*, 2007, **17**, 2695–2699.
- 91 R. Wang, R. Xiao, Z. Zeng, L. Xu and J. Wang, *Int. J. Nanomed.*, 2012, **7**, 4185–4198.
- 92 P. Howes, M. Green, J. Levitt, K. Suhling and M. Hughes, *J. Am. Chem. Soc.*, 2010, **132**, 3989–3996.
- 93 K. Y. Pu, L. Cai and B. Liu, *Macromolecules*, 2009, **42**, 5933–5940.
- 94 D. Ding, J. Liu, G. Feng, K. Li, Y. Hu and B. Liu, *Small*, 2013, **9**, 3093–3102.



- 95 G. Feng, K. Li, J. Liu, D. Ding and B. Liu, *Small*, 2014, **10**, 1212–1219.
- 96 K. Pu, A. J. Shuhendler and J. Rao, *Angew. Chem., Int. Ed.*, 2013, **125**, 10515–10519.
- 97 K. Maruyama, T. Yuda, A. Okamoto, S. Kojima, A. Suqinaka and M. Lwatsuru, *Biochim. Biophys. Acta*, 1992, **1128**, 44–49.
- 98 C. Wu, Y. Jin, T. Schneider, D. R. Burnham, P. B. Smith and D. T. Chiu, *Angew. Chem., Int. Ed.*, 2010, **49**, 9436–9440.
- 99 F. Ye, C. Wu, Y. Jin, M. Wang, Y.-H. Chan, J. Yu, W. Sun, S. Hayden and D. T. Chiu, *Chem. Commun.*, 2012, **48**, 1778–1780.
- 100 S. R. Amrutha and M. Jayakannan, *J. Phys. Chem.*, 2008, **112**, 1119–1129.
- 101 K. Li and B. Liu, *Polym. Chem.*, 2010, **1**, 252–259.
- 102 K. Jeong, S. Park, Y.-D. Lee, C.-K. Lim, J. Kim, B. H. Chung, I. C. Kwon, C. R. Park and S. Kim, *Adv. Mater.*, 2013, **25**, 5574–5580.
- 103 Z. Tian, J. Yu, C. Wu, C. Szymanski and J. McNeill, *Nanoscale*, 2010, **2**, 1999–2011.
- 104 F. Ye, C. Wu, Y. Jin, Y.-H. Chan, X. Zhang and D. T. Chiu, *J. Am. Chem. Soc.*, 2011, **133**, 8146–8149.
- 105 Y.-H. Chan, C. Wu, F. Ye, Y. Jin, P. B. Smith and D. T. Chiu, *Anal. Chem.*, 2011, **83**, 1448–1455.
- 106 M. Irie, T. Fukaminato, T. Sasaki, N. Tamai and T. Kawai, *Nature*, 2002, **420**, 759–760.
- 107 M. Hofmann, C. Eggeling, S. Jakobs and S. W. Hell, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 17565–17569.
- 108 R. Ando, H. Mizuno and A. Miyawaki, *Science*, 2004, **306**, 1370–1373.
- 109 Y. Osakada, L. Hanson and B. Cui, *Chem. Commun.*, 2012, **48**, 3285–3287.
- 110 G. Feng, D. Ding, K. Li, J. Liu and B. Liu, *Nanoscale*, 2014, **6**, 4141–4147.
- 111 Y.-H. Chan, M. E. Gallina, X. Zhang, I.-C. Wu, Y. Jin, W. Sun and D. T. Chiu, *Anal. Chem.*, 2012, **84**, 9431–9438.
- 112 C. Wu, S. J. Hansen, Q. Hou, J. Yu, M. Zeigler, Y. H. Jin, D. R. Burnham, J. D. McNeill, J. M. Olson and D. T. Chiu, *Angew. Chem., Int. Ed.*, 2011, **50**, 3430–3434.
- 113 A. L. Koner, D. Krndija, Q. Hou, D. J. Sherratt and M. Howarth, *ACS Nano*, 2013, **7**, 1137–1144.
- 114 *Tissue optics*, ed. V. Tuchin, SPIE Press, Bellingham, Washington, 2000.
- 115 M.-K. So, C. Xu, A. M. Loening, S. S. Gambhir and J. Rao, *Nat. Biotechnol.*, 2006, **24**, 339–343.
- 116 L. Xiong, A. J. Shuhendler and J. Rao, *Nat. Commun.*, 2012, **3**, 1193.
- 117 Y. Jin, F. Ye, C. Wu, Y.-H. Chan and D. T. Chiu, *Chem. Commun.*, 2012, **48**, 3161–3163.
- 118 J. Geng, C. C. Goh, N. Tomczak, J. Liu, R. Liu, L. Ma, L. G. Ng, G. G. Gurzadyan and B. Liu, *Chem. Mater.*, 2014, **26**, 1874–1880.
- 119 H. Tan, Y. Zhang, M. Wang, Z. Zhang, X. Zhang, A. M. Yong, S. Y. Wong, A. Y. Chang, Z. K. Chen, X. Li, M. Choolani and J. Wang, *Biomaterials*, 2012, **33**, 237–246.
- 120 D. Polli, G. Grancini, J. Clark, M. Celebrano, T. Virgili, G. Cerullo and G. Lanzani, *Adv. Mater.*, 2010, **22**, 3048–3051.
- 121 Z. Chi, X. Zhang, B. Xu, X. Zhou, C. Ma, Y. Zhang, S. Liu and J. Xu, *Chem. Soc. Rev.*, 2012, **41**, 3878–3896.
- 122 J. Luo, Z. Xie, J. W. Y. Lam, L. Cheng, H. Chen, C. Qiu, H. S. Kwok, X. Zhan, Y. Liu, D. Zhu and B. Z. Tang, *Chem. Commun.*, 2001, **18**, 1740–1741.
- 123 Y. Hong, J. W. Y. Lam and B. Z. Tang, *Chem. Commun.*, 2009, 4332–4353.
- 124 G. Qian and Z. Y. Wang, *Chem. – Asian J.*, 2010, **5**, 1006–1029.
- 125 F. Ito, R. Ohta, Y. Yokota, K. Ueno, H. Misawa and T. Nagamura, *Opt. Photonics J.*, 2013, **3**, 27–31.
- 126 Q. Zhao, K. Li, S. Chen, A. Qin, D. Ding, S. Zhang, Y. Liu, B. Liu, J. Z. Sun and B. Z. Tang, *J. Mater. Chem.*, 2012, **22**, 15128–15135.
- 127 W. Qin, D. Ding, J. Liu, W. Z. Yuan, Y. Hu, B. Liu and B. Z. Tang, *Adv. Funct. Mater.*, 2012, **22**, 771–779.
- 128 Z. Wang, S. Chen, J. W. Y. Lam, W. Qin, R. T. K. Kwok, N. Xie, Q. Hu and B. Z. Tang, *J. Am. Chem. Soc.*, 2013, **135**, 8238–8245.
- 129 X. Zhang, X. Zhang, B. Yang, M. Liu, W. Liu, Y. Chen and Y. Wei, *Polym. Chem.*, 2013, **4**, 4317–4321.
- 130 *Frontiers in Chemical Sensors: Novel Principles and Techniques*, ed. G. Orellana and M. C. Moreno-Bondi, Springer, Berlin, 2010.
- 131 K. Li, Y. Jiang, D. Ding, X. Zhang, Y. Liu, J. Hua, S. S. Feng and B. Liu, *Chem. Commun.*, 2011, **47**, 7323–7325.
- 132 K. Li, W. Qin, D. Ding, N. Tomczak, J. Geng, R. Liu, J. Liu, X. Zhang, H. Liu, B. Liu and B. Z. Tang, *Sci. Rep.*, 2013, **3**, 1150.
- 133 D. Wang, J. Qian, W. Qin, A. Qin, B. Z. Tang and S. He, *Sci. Rep.*, 2014, **4**, 4279.
- 134 K. Li, Z. Zhu, P. Cai, R. Liu, N. Tomczak, D. Ding, J. Liu, W. Qin, Z. Zhao, Y. Hu, X. Chen, B. Z. Tang and B. Liu, *Chem. Mater.*, 2013, **25**, 4181–4187.
- 135 K. Li, D. Ding, C. Prashant, W. Qin, C.-T. Yang, B. Z. Tang and B. Liu, *Adv. Healthcare Mater.*, 2013, **2**, 1600–1605.
- 136 W. Qin, K. Li, G. Feng, M. Li, Z. Yang, B. Liu and B. Z. Tang, *Adv. Funct. Mater.*, 2014, **24**, 635–643.
- 137 D. Ding, C. C. Goh, G. Feng, Z. Zhao, J. Liu, R. Liu, N. Tomczak, J. Geng, B. Z. Tang, L. G. Ng and B. Liu, *Adv. Mater.*, 2013, **25**, 6083–6088.
- 138 Z. Xie, B. Yang, W. Xie, L. Liu, F. Shen, H. Wang, X. Yang, Z. Wang, Y. Li, M. Hanif, G. Yang, L. Ye and Y. Ma, *J. Phys. Chem. B*, 2006, **110**, 20993–21000.
- 139 J. Geng, Z. Zhu, W. Qin, L. Ma, Y. Hu, G. G. Gurzadyan, B. Z. Tang and B. Liu, *Nanoscale*, 2014, **6**, 939–945.
- 140 Y. Dong, B. Xu, J. Zhang, X. Tan, L. Wang, J. Chen, H. Lv, S. Wen, B. Li, L. Ye, B. Zou and W. Tian, *Angew. Chem., Int. Ed.*, 2012, **51**, 10782–10785.
- 141 J. Geng, K. Li, W. Qin, L. Ma, G. G. Gurzadyan, B. Z. Tang and B. Liu, *Small*, 2013, **9**, 2012–2019.
- 142 Y. Yang, F. An, Z. Liu, X. Zhang, M. Zhou, W. Li, X. Hao, C.-S. Lee and X. Zhang, *Biomaterials*, 2012, **33**, 7803–7809.
- 143 W.-C. Wu, C.-Y. Chen, Y. Tian, S.-H. Jang, Y. Hong, Y. Liu, R. Hu, B. Z. Tang, Y.-T. Lee, C. T. Chen, W.-C. Chen and A. K.-Y. Jen, *Adv. Funct. Mater.*, 2010, **20**, 1413–1423.



- 144 D. Ding, K. Li, W. Qin, R. Zhan, Y. Hu, J. Liu, B. Z. Tang and B. Liu, *Adv. Healthcare Mater.*, 2013, **2**, 500–507.
- 145 X. Zhang, X. Zhang, B. Yang, M. Liu, W. Liu, Y. Chen and Y. Wei, *Polym. Chem.*, 2014, **5**, 356–360.
- 146 X. Zhang, M. Liu, B. Yang, X. Zhang, Z. Chi, S. Liu, J. Xu and Y. Wei, *Polym. Chem.*, 2013, **4**, 5060–5064.
- 147 X. Zhang, X. Zhang, B. Yang, J. Hui, M. Liu, Z. Chi, S. Liu, J. Xu and Y. Wei, *Polym. Chem.*, 2014, **5**, 318–322.
- 148 X. Zhang, X. Zhang, B. Yang, M. Liu, W. Liu, Y. Chen and Y. Wei, *Polym. Chem.*, 2014, **5**, 399–404.
- 149 H. J. Dou, M. Jiang, H. S. Peng, D. Y. Chen and Y. Hong, *Angew. Chem., Int. Ed.*, 2003, **42**, 1516–1519.
- 150 H. Lu, F. Sum, Q. Mei, Y. Tian, W. Tian, R. H. Johnson and D. R. Meldrum, *J. Mater. Chem.*, 2012, **22**, 9890–9900.
- 151 D. Razansky, C. Vinegoni and V. Ntziachristos, *Opt. Lett.*, 2007, **32**, 2891–2893.
- 152 M. S. Patterson, B. Chance and B. C. Wilson, *Appl. Opt.*, 1989, **28**, 2331–2336.
- 153 V. Ntziachristos, *Nat. Methods*, 2010, **7**, 603–614.
- 154 V. Ntziachristos and D. Razansky, *Chem. Rev.*, 2010, **110**, 2783–2794.
- 155 M. H. Xu and L. H. V. Wang, *Rev. Sci. Instrum.*, 2006, **77**, 041101.
- 156 X. M. Yang, S. E. Skrabalak, Z. Y. Li, Y. N. Xia and L. H. V. Wang, *Nano Lett.*, 2007, **7**, 3798–3802.
- 157 Y. N. Xia, W. Y. Li, C. M. Cobley, J. Y. Chen, X. H. Xia, Q. Zhang, M. X. Yang, E. C. Cho and P. K. Brown, *Acc. Chem. Res.*, 2011, **44**, 914–924.
- 158 Y. D. Jin, C. X. Jia, S. W. Huang, M. O'Donnell and X. H. Gao, *Nat. Commun.*, 2010, **1**, 41.
- 159 J. W. Kim, E. I. Galanzha, E. V. Shashkov, H. M. Moon and V. P. Zharov, *Nat. Nanotechnol.*, 2009, **4**, 688–694.
- 160 Z. Liu, S. Tabakman, K. Welscher and H. J. Dai, *Nano Res.*, 2009, **2**, 85–120.
- 161 X. D. Wang, G. Ku, M. A. Wegiel, D. J. Bornhop, G. Stoica and L. H. V. Wang, *Opt. Lett.*, 2004, **29**, 730–732.
- 162 C. Kim, K. H. Song, F. Gao and L. H. V. Wang, *Radiology*, 2010, **255**, 442–450.
- 163 G. Kim, S. W. Huang, K. C. Day, M. O'Donnell, R. R. Agayan, M. A. Day, R. Kopelman and S. Ashkenazi, *J. Biomed. Opt.*, 2007, **12**, 044020.
- 164 W. J. Akers, C. Kim, M. Berezin, K. Guo, R. Fuhrhop, G. M. Lanza, G. M. Fischer, E. Daltrozzi, A. Zumbusch, X. Cai, L. V. Wang and S. Achilefu, *ACS Nano*, 2011, **5**, 173–182.
- 165 A. de la Zerda, S. Bodapati, R. Teed, S. Y. May, S. M. Tabakman, Z. Liu, B. T. Khuri-Yakub, X. Y. Chen, H. J. Dai and S. S. Gambhir, *ACS Nano*, 2012, **6**, 4694–4701.
- 166 J. Jang and H. Yoon, *Small*, 2005, **1**, 1195–1199.
- 167 J.-Y. Hong, H. Yoon and J. Jang, *Small*, 2010, **6**, 679–686.
- 168 O. S. Kwon, S. J. Park and J. Jang, *Biomaterials*, 2010, **31**, 4740–4747.
- 169 H. Yoon, S. H. Lee, O. S. Kwon, H. S. Song, E. H. Oh, T. H. Park and J. Jang, *Angew. Chem., Int. Ed.*, 2009, **48**, 2755–2758.
- 170 M. B. Runge, M. Dadsetan, J. Baltrusaitis, T. Ruesink, L. Lu, A. J. Windebank and M. J. Yaszemski, *Biomacromolecules*, 2010, **11**, 2845–2853.
- 171 Z. Zha, Z. Deng, Y. Li, C. Li, J. Wang, S. Wang, E. Qu and Z. Dai, *Nanoscale*, 2013, **5**, 4462–4467.
- 172 J. Liu, J. Geng, L.-D. Liao, N. Thakor, X. Gao and B. Liu, *Polym. Chem.*, 2014, **5**, 2854–2862.
- 173 K. Pu, A. J. Shuhendler, J. V. Jokerst, J. Mei, S. S. Gambhir, Z. Bao and J. Rao, *Nat. Nanotechnol.*, 2014, **9**, 233–239.
- 174 L. Xu, L. Cheng, C. Wang, R. Peng and Z. Liu, *Polym. Chem.*, 2014, **5**, 1573–1580.
- 175 Z. Zha, X. Yue, Q. Ren and Z. Dai, *Adv. Mater.*, 2013, **25**, 777–782.
- 176 L. Cheng, K. Yang, Q. Chen and Z. Liu, *ACS Nano*, 2012, **6**, 5605–5613.

